# EDGAR Filing Document

**Accession Number:** 0001731348
**File Stem:** 0001437749-26-000902
**Filing Date:** 2026-1
**Character Count:** 198404
**Document Hash:** 078c52ee8d66cb0f7575c1ba2c8a446b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-000902.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0001437749-26-000902

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 118

**CONFORMED PERIOD OF REPORT**: 20251130

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tilray Brands, Inc.
- **CENTRAL INDEX KEY:** 0001731348
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824310622
- **FISCAL YEAR END:** 0531

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38594
- **FILM NUMBER:** 26520500

**BUSINESS ADDRESS:**
- **STREET 1:** 655 MADISON AVENUE
- **STREET 2:** 19TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065
- **BUSINESS PHONE:** 519.322.8800

**MAIL ADDRESS:**
- **STREET 1:** 655 MADISON AVENUE
- **STREET 2:** 19TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tilray, Inc.
- **DATE OF NAME CHANGE:** 20180213

?xml version='1.0' encoding='ASCII'? tlry20251130_10q.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

------

**FORM 10-Q**

------

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended November 30, 2025**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from to** 

**Commission File Number: 001-38594**

------

## TILRAY BRANDS, INC.
**(Exact Name of Registrant as Specified in its Charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **82-4310622** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **265 Talbot Street West,**<br> **Leamington, ON** | **N8H 5L4** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant**'**s telephone number, including area code: (844) 845-7291**

------

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br> **Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | TLRY | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &nbsp;&nbsp;&nbsp;&nbsp;Yes ☐&nbsp;&nbsp;&nbsp;&nbsp;No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. &nbsp;&nbsp;&nbsp;&nbsp;Yes ☒&nbsp;&nbsp;&nbsp;&nbsp;No ☐

As of January 6, 2026, the registrant had 116,506,916 shares of Common Stock, $0.0001 par value per share issued and outstanding.

------

**Table of Contents**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| [**PART I.**](#bs) | [FINANCIAL INFORMATION](#bs) | [1](#bs) |
| [Item 1.](#bs) | [Financial Statements (Unaudited)](#bs) | [1](#bs) |
|  | [Consolidated Statements of Financial Position (Unaudited)](#bs) | [1](#bs) |
|  | [Consolidated Statements of Loss and Comprehensive Loss (Unaudited)](#income) | [2](#income) |
|  | [Consolidated Statements of Stockholders' Equity (Unaudited)](#equity) | [3](#equity) |
|  | [Consolidated Statements of Cash Flows (Unaudited)](#cashflows) | [4](#cashflows) |
|  | [Notes to Condensed Interim Consolidated Financial Statements (Unaudited)](#notes) | [5](#notes) |
| [Item 2.](#mda) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#mda) | [24](#mda) |
| [Item 3.](#qqdmr) | [Quantitative and Qualitative Disclosures About Market Risk](#qqdmr) | [45](#qqdmr) |
| [Item 4.](#cps) | [Controls and Procedures](#cps) | [45](#cps) |
| [**PART II.**](#partii) | [OTHER INFORMATION](#partii) | [46](#partii) |
| [Item 1.](#legal) | [Legal Proceedings](#legal) | [46](#legal) |
| [Item 1A.](#risks) | [Risk Factors](#risks) | [47](#risks) |
| [Item 2.](#uses) | [Unregistered Sales of Equity Securities and Use of Proceeds](#uses) | [48](#uses) |
| [Item 3.](#duss) | [Defaults Upon Senior Securities](#duss) | [48](#duss) |
| [Item 4.](#msd) | [Mine Safety Disclosures](#msd) | [48](#msd) |
| [Item 5.](#otherinfo) | [Other Information](#otherinfo) | [48](#otherinfo) |
| [Item 6.](#exs) | [Exhibits](#exs) | [49](#exs) |
| [Signatures](#sigs) | [Signatures](#sigs) | [51](#sigs) |

---

------

**Cautionary Note Regarding Forward-Looking Statements** 

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include, but are not limited to, those identified in this Form 10-Q and other risks and matters described in our most recent Annual Report on Form 10-K for the fiscal year ended May 31, 2025 as well as our other filings made from time to time with the U.S. Securities and Exchange Commission and in our Canadian securities filings.

Forward looking statements are based on information available to us as of the date of this Form 10-Q and, while we believe that information provides a reasonable basis for these statements, these statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

------

**PART I**—**FINANCIAL INFORMATION**

**Item 1. Financial Statements (Unaudited).**

**TILRAY BRANDS, INC.**

**Consolidated Statements of Financial Position** 

**(in thousands of United States dollars, unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| **Assets** |  |  |
| **Current assets** |  |  |
| Cash and cash equivalents | $246703 | $221666 |
| Marketable securities | 44848 | 34697 |
| Accounts receivable, net | 109071 | 121489 |
| Inventory | 283198 | 270882 |
| Prepaids and other current assets | 41497 | 34092 |
| Assets held for sale | 4000 | 5800 |
| **Total current assets** | 729317 | 688626 |
| Capital assets | 550101 | 568433 |
| Operating lease, right-of-use assets | 19802 | 22279 |
| Digital assets | 828 |  |
| Intangible assets | 21735 | 21423 |
| Goodwill | 752350 | 752350 |
| Long-term investments | 13393 | 10132 |
| Other assets | 11073 | 11084 |
| **Total assets** | $2098599 | $2074327 |
| **Liabilities** |  |  |
| **Current liabilities** |  |  |
| Bank indebtedness | $8567 | $7181 |
| Accounts payable and accrued liabilities | 226422 | 235322 |
| Contingent consideration |  | 15000 |
| Warrant liability |  | 1092 |
| Current portion of lease liabilities | 7437 | 6941 |
| Current portion of long-term debt | 16889 | 14767 |
| **Total current liabilities** | 259315 | 280303 |
| **Long - term liabilities** |  |  |
| Lease liabilities | 61742 | 64925 |
| Long-term debt | 138739 | 148493 |
| Convertible debentures payable | 86255 | 86428 |
| Deferred tax liabilities, net | 5622 | 3748 |
| Other liabilities | 417 | 855 |
| **Total liabilities** | 552090 | 584752 |
| **Commitments and contingencies (refer to Note 19)** |  |  |
| **Stockholders' equity** |  |  |
| Common stock ($0.0001 par value; 1,416,000,000 common shares authorized; 116,522,600 and 106,067,875 common shares issued and outstanding, respectively)<sup>1</sup> | 116 | 106 |
| Treasury Stock (321,391 and 200,422 treasury shares issued and outstanding, respectively)<sup>1</sup> |  |  |
| Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively) |  |  |
| Additional paid-in capital | 6511483 | 6401657 |
| Accumulated other comprehensive loss | (39293) | (43063) |
| Accumulated deficit | (4892479) | (4847226) |
| **Total Tilray Brands, Inc. stockholders' equity** | 1579827 | 1511474 |
| Non-controlling interests | (33318) | (21899) |
| **Total stockholders' equity** | 1546509 | 1489575 |
| **Total liabilities and stockholders' equity** | $2098599 | $2074327 |

---

<sup>1</sup>Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split (as defined below), which became effective on December 2, 2025. See Note 1 for details.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

**TILRAY BRANDS, INC.**

**Consolidated Statements of Loss and Comprehensive Loss**

**(in thousands of United States dollars, except for share and per share data, unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Three months ended*** | ***Three months ended*** | ***Six months ended*** | ***Six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Net revenue | $217507 | $210950 | $427008 | $410994 |
| Cost of goods sold | 160010 | 149730 | 312042 | 290068 |
| Gross profit | 57497 | 61220 | 114966 | 120926 |
| Operating expenses: |  |  |  |  |
| General and administrative | 51175 | 45997 | 92228 | 90110 |
| Selling | 11781 | 16162 | 24704 | 27852 |
| Amortization | 4358 | 22927 | 8287 | 44731 |
| Marketing and promotion | 9981 | 9720 | 20136 | 21286 |
| Research and development | 78 | 60 | 119 | 165 |
| Change in fair value of contingent consideration |  |  | (15000) |  |
| Litigation costs, net of recoveries | 869 | 901 | 1876 | 2496 |
| Restructuring costs | 965 | 6869 | 1834 | 11116 |
| Transaction costs (income), net | 569 | 802 | 969 | 1958 |
| Total operating expenses | 79776 | 103438 | 135153 | 199714 |
| Operating loss | (22279) | (42218) | (20187) | (78788) |
| Interest expense, net | (5374) | (7766) | (12070) | (17608) |
| Non-operating income (expense), net | (12310) | (33255) | (8478) | (20609) |
| Loss before income taxes | (39963) | (83239) | (40735) | (117005) |
| Income tax expense (recovery), net | 3546 | 2036 | 1261 | 2922 |
| Net loss | $(43509) | $(85275) | $(41996) | $(119927) |
| Total net income (loss) attributable to: |  |  |  |  |
| Stockholders of Tilray Brands, Inc. | (44931) | (85342) | (45253) | (124507) |
| Non-controlling interests | 1422 | 67 | 3257 | 4580 |
| Other comprehensive gain (loss), net of tax |  |  |  |  |
| Foreign currency translation gain (loss) | 4464 | (8966) | 4276 | (4806) |
| Comprehensive loss | $(39045) | $(94241) | $(37720) | $(124733) |
| Total comprehensive income (loss) attributable to: |  |  |  |  |
| Stockholders of Tilray Brands, Inc. | (40994) | (93422) | (41483) | (128965) |
| Non-controlling interests | 1949 | (819) | 3763 | 4232 |
| Weighted average number of common shares - basic<sup>1</sup> | 110343368 | 86497456 | 108173486 | 83740894 |
| Weighted average number of common shares - diluted<sup>1</sup> | 110343368 | 86497456 | 108173486 | 83740894 |
| Net loss per share - basic<sup>1</sup> | $(0.41) | $(0.99) | $(0.42) | $(1.49) |
| Net loss per share - diluted<sup>1</sup> | $(0.41) | $(0.99) | $(0.42) | $(1.49) |

---

<sup>1</sup>Current and prior year share and amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025. See Note 1 for details.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

**TILRAY BRANDS, INC.**

**Consolidated Statements of Stockholders**' **Equity**

**(in thousands of United States dollars, except for share data, unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  |  | ***Accumulated*** |  |  |  |
|  | ***Number of*** |  | ***Number of*** |  | ***Additional*** | ***other*** |  | ***Non-*** |  |
|  | ***common*** | ***Common*** | ***treasury*** | ***Treasury*** | ***paid-in*** | ***comprehensive*** | ***Accumulated*** | ***controlling*** |  |
|  | **shares<sup>1</sup>** | ***Stock*** | **shares<sup>1</sup>** | ***stock*** | ***capital*** | ***loss*** | ***Deficit*** | ***interests*** | ***Total*** |
| Balance at May 31, 2024 | 83192537 | $83 |  | $— | $6146810 | $(43499) | $(2660488) | $272 | $3443178 |
| Share issuance - At-the-Market ("ATM") program | 3669331 | 4 |  |  | 66468 |  |  |  | 66472 |
| Share issuance - RSUs exercised | 682314 | 1 |  |  | (1) |  |  |  |  |
| Share issuance - options exercised | 301 |  |  |  |  |  |  |  |  |
| Shares effectively repurchased for employee withholding tax | *—* |  | *—* |  | (2661) |  |  |  | (2661) |
| Stock-based compensation | *—* |  | *—* |  | 6917 |  |  |  | 6917 |
| Comprehensive income (loss) for the period | *—* |  | *—* |  |  | 3622 | (39165) | 5051 | (30492) |
| Balance at August 31, 2024 | 87544483 | $88 |  | $— | $6217533 | $(39877) | $(2699653) | $5323 | $3483414 |
| Share issuance - At-the-Market ("ATM") program | 3051756 | 3 |  |  | 45041 |  |  |  | 45044 |
| Share issuance - Repurchase of TLRY 27 convertible note | 1003464 | 1 | (368261) |  | 17084 |  |  |  | 17085 |
| Share issuance - Settlement of equity component of TLRY 27 convertible note | *—* |  | *—* |  | (4931) |  |  |  | (4931) |
| Share issuance - Double Diamond Holdings dividend settlement | 1321759 | 1 |  |  | 23823 |  |  | (23824) |  |
| Share issuance - RSUs exercised | 3598 |  |  |  |  |  |  |  |  |
| Share issuance - options exercised | 735 |  |  |  |  |  |  |  |  |
| Stock-based compensation | *—* |  | *—* |  | 7237 |  |  |  | 7237 |
| Comprehensive loss for the period | *—* |  | *—* |  |  | (8080) | (85342) | (819) | (94241) |
| Balance at November 30, 2024 | 92925795 | 93 | (368261) |  | 6305787 | (47957) | (2784995) | (19320) | 3453608 |
| Balance at May 31, 2025 | 106067875 | $106 | (200422) | $— | $6401657 | $(43063) | $(4847226) | $(21899) | $1489575 |
| Share issuance - At-the-Market ("ATM") program | 3444380 | 3 |  |  | 22488 |  |  |  | 22491 |
| Share issuance - Repurchase of TLRY 27 convertible note | 1259182 | 1 | (120969) |  | 4799 |  |  |  | 4800 |
| Share issuance - Settlement of equity component of TLRY 27 convertible note | *—* |  | *—* |  | (1158) |  |  |  | (1158) |
| Share issuance - RSUs exercised | 1057680 | 1 |  |  | (1) |  |  |  |  |
| Shares effectively repurchased for employee withholding tax | *—* |  | *—* |  | (1427) |  |  |  | (1427) |
| Stock-based compensation | *—* |  | *—* |  | 5052 |  |  |  | 5052 |
| Comprehensive income (loss) for the period | *—* |  | *—* |  |  | (167) | (322) | 1814 | 1325 |
| Balance at August 31, 2025 | 111829117 | $111 | (321391) | $— | $6431410 | $(43230) | $(4847548) | $(20085) | $1520658 |
| Share issuance - At-the-Market ("ATM") program | 3332844 | 3 |  |  | 50562 |  |  |  | 50565 |
| Share issuance - RSUs exercised, net of cancellations | (121968) |  |  |  |  |  |  |  |  |
| Share issuance - Warrant exercised | 620900 | 1 |  |  | 6954 |  |  |  | 6955 |
| Share issuance - Double Diamond Holdings dividend settlement | 861707 | 1 |  |  | 14821 |  |  | (15182) | (360) |
| Stock-based compensation | *—* |  | *—* |  | 7736 |  |  |  | 7736 |
| Comprehensive income (loss) for the period | *—* |  | *—* |  |  | 3937 | (44931) | 1949 | (39045) |
| Balance at November 30, 2025 | 116522600 | $116 | (321391) | $— | $6511483 | $(39293) | $(4892479) | $(33318) | $1546509 |

---

<sup>1</sup>Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on December 2, 2025. See Note 1 for details.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

**TILRAY BRANDS, INC.**

**Consolidated Statements of Cash Flows**

**(in thousands of United States dollars, unaudited)**

---

| | | |
|:---|:---|:---|
|  | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** |
| **Cash provided by (used in) operating activities:** |  |  |
| Net loss | $(41996) | $(119927) |
| Adjustments for: |  |  |
| Deferred income tax (recovery) expense, net | 1261 | 1529 |
| Unrealized foreign exchange gain | 4899 | 9627 |
| Amortization | 31519 | 65864 |
| Accretion of convertible debt discount | 3964 | 5985 |
| Unrealized loss on digital assets | 172 |  |
| Other non-cash items | 1767 | 3281 |
| Stock-based compensation | 17335 | 14154 |
| Gain on long-term investments | 306 | 66 |
| Loss (gain) on derivative instruments | 3495 | (1558) |
| Change in fair value of contingent consideration | (15000) |  |
| Change in non-cash working capital: |  |  |
| Accounts receivable | 12418 | (9051) |
| Prepaids and other current assets | (7394) | (13046) |
| Inventory | (12316) | (8127) |
| Accounts payable and accrued liabilities | (10308) | (24828) |
| Net cash used in operating activities | (9878) | (76031) |
| **Cash provided by (used in) investing activities:** |  |  |
| Investment in capital and intangible assets | (19219) | (12172) |
| Proceeds from disposal of capital and intangible assets | 427 | 631 |
| Investment in digital assets | (1000) |  |
| Purchase of marketable securities, net | (10151) | (30369) |
| Investment in long-term investments | (3595) |  |
| Business acquisitions, net of cash acquired |  | (18210) |
| Net cash used in investing activities | (33538) | (60120) |
| **Cash provided by (used in) financing activities:** |  |  |
| Share capital issued, net of cash issuance costs | 73058 | 111517 |
| Proceeds from warrants exercised | 2367 |  |
| Repayment of long-term debt | (6872) | (10388) |
| Repayment of convertible debt |  | (330) |
| Repayment of lease liabilities | (1991) | (1724) |
| Net decrease in bank indebtedness | 1386 | (282) |
| Net cash provided by financing activities | 67948 | 98793 |
| Effect of foreign exchange on cash and cash equivalents | 505 | (1284) |
| Net increase (decrease) in cash and cash equivalents | 25037 | (38642) |
| Cash and cash equivalents, beginning of period | 221666 | 228340 |
| Cash and cash equivalents, end of period | $246703 | $189698 |

---

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

**TILRAY BRANDS, INC.**

**Notes to Consolidated Financial Statements**

**Note *1.* Basis of presentation and summary of significant accounting policies** 

The accompanying unaudited interim consolidated financial statements reflect the accounts of the Company for the quarterly period ended *November 30, 2025* (the "Financial Statements"). The Financial Statements were prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do *not* include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the "Annual Financial Statements") included in the Company's Annual Report on Form *10*-K for the fiscal year ended *May 31, 2025* (the "Annual Report"). These Financial Statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are *not* necessarily indicative of results for the full fiscal year.

The Financial Statements have been prepared on a going concern basis, which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company's accounting policies.

All amounts in the Financial Statements, and the accompanying notes and tables have been rounded to the nearest thousand, except par values and per share amounts, and unless otherwise indicated.

*Basis of consolidation*

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of all subsidiaries are included in the Financial Statements from the date that control commences until the date that control ceases. All intercompany balances and transactions have been eliminated on consolidation. A complete list of our subsidiaries that existed as of our most recent fiscal year end is included in the Annual Report.

*Reverse Stock Split*

Effective *December 2, 2025,* the Company implemented a reverse stock split of its outstanding shares of Common Stock, at a ratio of *one*-for-ten (the "Reverse Stock Split").

All issued and outstanding Common Stock, per share amounts, and outstanding equity instruments and awards exercisable into Common Stock contained in the condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Reverse Stock Split for all prior periods presented.

*Earnings (loss) per share*

Basic earnings (loss) per share is computed by dividing reported net loss attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net loss attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of Common Stock outstanding under the share lending arrangement entered into in conjunction with the TLRY *27* Notes, see Note *12* (Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.

In computing diluted earnings (loss) per share, common share equivalents are *not* considered in periods in which a net loss attributable to Tilray shareholders is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the *three* months ended *November 30, 2025* and *November 30, 2024*, the dilutive potential common share equivalents outstanding consisted of the following: 7,734,265.and 2,336,535 common shares from RSUs, 303,203 and 306,032 common shares from share options, nil and 620,900 common shares for warrants and 3,766,478 and 5,875,706 common shares for convertible debentures, respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on *December 2, 2025.* 

*New accounting pronouncements *not* yet adopted*

In *August 2023,* the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *2023*-*05,* Business Combination - Joint Venture Formations (Subtopic *805*-*60*) Recognition and Initial Measurement ("ASU *2023*-*05"*), which is intended to address the accounting for contributions made to a joint venture. ASU *2023*-*05* is effective for the Company beginning *June 1, 2026.* This update will be applied prospectively and the Company is currently evaluating the effect of adopting this ASU.

In *October 2023,* the FASB issued ASU *2023*-*06,* Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative, which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the "Codification"). The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-*X* or Regulation S-K becomes effective, with early adoption prohibited. If by *June 30, 2027,* the SEC has *not* removed the applicable requirement from Regulation S-*X* or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will *not* become effective for any entity. The Company is currently evaluating the effect of adopting this ASU.

In *December 2023,* the FASB issued ASU *2023*-*09,* Income Taxes (Topic *740*) Improvements to Income Tax Disclosures, which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU *2023*-*09* is effective for the Company beginning with its fiscal year ended *May 31, 2026* and will be disclosed in the Financial Statements reported in our Annual Report on Form *10*-K filed with the SEC for such period. The Company is in the process of evaluating the impact of the financial statement disclosure requirement.

In *November 2024,* the FASB issued ASU *2024*-*03,* Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic *220*-*40*): Disaggregation of Income Statement Expenses, which requires disaggregated disclosure of income statement expenses for public business entities. ASU *2024*-*03* is effective for the Company beginning fiscal year ended *May 31, 2028* and will be disclosed in the Annual Report on Form *10*-K. The Company is currently evaluating the effect of adopting this ASU.

*New accounting pronouncements recently adopted*

In *November 2024,* the FASB issued ASU *2024*-*04,* Debt with Conversion and Other Options (Subtopic *470*-*20*): Induced Conversions of Convertible Debt Instruments, which seeks to clarify the requirements for determining whether certain settlements of convertible debt instruments should be accounted for as an induced conversion. The Company adopted ASU *2024*-*04* beginning *June 1, 2025,* however, it did *not* have any impact on our unaudited interim consolidated financial statements.

*Digital Assets*

In *December 2023,* FASB issued ASU *2023*-*08,* Intangibles—Goodwill and Other—Crypto Assets (Subtopic *350*-*60*): Accounting for and Disclosure of Crypto Assets. ASU *2023*-*08* requires certain crypto assets to be measured at fair value separately on the balance sheet with gains and losses from changes in the fair value reported as unrealized gains or losses in the consolidated statement of income (loss) and comprehensive income (loss) each reporting period. ASU *2023*-*08* also enhances the other intangible asset disclosure requirements by requiring the name, cost basis, fair value, and number of units for each significant crypto asset holding. In conjunction with the acquisition of digital assets during the fiscal quarter ended *August 31, 2025,* the Company adopted and applied ASU-*2023*-*08* henceforth.

The Company's digital assets are initially recorded at cost, and are subsequently measured at fair value as of each reporting period. The Company determines the fair value of its digital assets in accordance with ASC *820,* Fair Value Measurement, based on quoted prices in its principal market for Bitcoin (Level *1*). Changes in fair value are recognized as incurred in the Company's consolidated statement of income (loss) and comprehensive income (loss), as "Unrealized (gain) loss on digital assets," within non-operating (income) and expenses, net.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *5*

------

**Note *2.* Inventory**

Inventory consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| Beverage inventory | $67363 | $63965 |
| Cannabis plants | 29117 | 24045 |
| Dried cannabis | 106114 | 103507 |
| Cannabis derivatives | 3798 | 7877 |
| Cannabis vapes | 1639 | 1860 |
| Packaging and other inventory items | 13532 | 15366 |
| Distribution inventory | 48104 | 38735 |
| Wellness inventory | 13531 | 15527 |
| Total | $283198 | $270882 |

---

**Note *3.* Capital assets**

Capital assets consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| Land | $45188 | $44529 |
| Production facilities | 415110 | 407650 |
| Equipment | 278205 | 280585 |
| Leasehold improvements | 22060 | 20415 |
| Finance lease, right-of-use assets | 39406 | 40308 |
| Construction in progress | 12469 | 11241 |
|  | $812438 | $804728 |
| Less: accumulated amortization | (262337) | (236295) |
| Total | $550101 | $568433 |

---

Assets held for sale consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| Production facilities | $4000 | $5800 |
| Total | $4000 | $5800 |

---

As of *November 30, 2025*, the Company classified the Fort Collins, CO partially vacant warehouse facility from its Cannabis reporting segment as held for sale. During the *three* months ended *November 30, 2025*, the Company recorded a reduction in fair value of $1,800 for the Fort Collins, CO asset group in the consolidated statement of loss and comprehensive loss. Subsequent to the period ended *November 30, 2025*, the Company completed the sale of the Fort Collins asset group.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *6*

------

**Note *4.* Leases**

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***November 30,*** | ***May 31,*** |
|  | ***Classification on Balance Sheet*** | ***2025*** | ***2025*** |
| **Assets** |  |  |  |
| Finance lease, right-of-use assets | *Capital assets* | $39406 | $40308 |
| Operating lease, right-of-use assets | *Operating lease, right-of-use assets* | 19802 | 22279 |
| *Total right-of-use assets* | *Total right-of-use assets* | $59208 | $62587 |
| **Liabilities** |  |  |  |
| Current: |  |  |  |
| Current portion of finance lease liabilities | *Current portion of lease liabilities* | $1628 | $1560 |
| Current portion of operating lease liabilities | *Current portion of lease liabilities* | 5809 | 5381 |
| Non-current: |  |  |  |
| Finance lease liabilities | *Lease liabilities* | 43597 | 44295 |
| Operating lease liabilities | *Lease liabilities* | 18145 | 20630 |
| *Total lease liabilities* | *Total lease liabilities* | $69179 | $71866 |

---

The following table presents the future undiscounted payments associated with lease liabilities as of *November 30, 2025*:

---

| | | |
|:---|:---|:---|
|  | ***Operating*** | ***Finance*** |
|  | ***leases*** | ***leases*** |
| 2026 (remaining six months) | $3711 | $2260 |
| 2027 | 6938 | 4521 |
| 2028 | 5920 | 4521 |
| 2029 | 2939 | 4373 |
| Thereafter | 11004 | 66816 |
| Total minimum lease payments | $30512 | $82491 |
| Imputed interest | (6558) | (37266) |
| Obligations recognized | $23954 | $45225 |

---

**Note *5.* Intangible Assets**

Intangible assets consisted of the following items:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Customer relationships & distribution channel*** | ***Licenses, permits & applications*** | ***Intellectual property, trademarks, knowhow & brands*** | ***November 30,*** |
|  |  |  |  | ***2025*** |
| Cost | $2376 | $15101 | $15466 | $32943 |
| Accumulated amortization | (100) | (7245) | (3863) | (11208) |
| Total | $2276 | $7856 | $11603 | $21735 |

---

As of *November 30, 2025,* the Company also has the following intangible assets which have been fully impaired; $444,208 of customer relationships and distribution channels, $367,022 of licenses, permits and applications, and $452,530 of intellectual property, trademarks, know-how and brands.

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Customer relationships & distribution channel** | **Licenses, permits & applications** | **Non-compete agreements** | **Intellectual property, trademarks, knowhow & brands** | **May 31,** |
|  |  |  |  |  | **2025** |
| Cost | $610240 | $387238 | $12449 | $618514 | $1628441 |
| Accumulated amortization | (166032) | (9693) | (12449) | (155084) | (343258) |
| Accumulated impairment losses | (444208) | (367022) |  | (452530) | (1263760) |
| Total | $— | $10523 | $— | $10900 | $21423 |

---

Licenses, permits & applications are predominantly comprised of multi-period sponsorship rights.

Expected future amortization expense for intangible assets as of *November 30, 2025* is as follows:

---

| | |
|:---|:---|
|  | ***Amortization*** |
| 2026 (remaining six months) | $3238 |
| 2027 | 6476 |
| 2028 | 4512 |
| 2029 | 2548 |
| 2030 | 2548 |
| Thereafter | 2413 |
| Total | $21735 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

**Note *6.* Goodwill**

The following table shows the carrying amount of goodwill by reporting units:

---

| | |
|:---|:---|
|  | ***November 30,*** |
|  | ***2025*** |
| Cannabis Goodwill | $2640669 |
| Accumulated impairment losses | (1888319) |
| Total | $752350 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***Reporting Unit*** | ***Reporting Unit*** | ***Reporting Unit*** | ***Reporting Unit*** | ***May 31,*** |
|  | ***Beverage*** | ***Cannabis*** | ***Wellness*** | ***Distribution*** | ***2025*** |
| Goodwill | $120802 | $2640669 | $77470 | $4458 | $2843399 |
| Accumulated impairment losses | (120802) | (1888319) | (68186) | (4235) | (2090654) |
| Effect of foreign exchange |  |  | (9284) | (223) | (395) |
| Total | $— | $752350 | $— | $— | $752350 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

**Note *7.*** **Business** **a** **cquisitions**

*<u>Acquisition of Craft</u> <u>Beverage Business Portfolio II</u>*

Effective *September 1, 2024,* the Company acquired four craft beer brands and breweries from Molson Coors Beverage Company ("Molson") including Atwater Brewery, Hop Valley Brewing Company, Terrapin Beer Co., and Revolver Brewing (the "Craft Acquisition II"). The purpose of the acquisition was to continue broadening Tilray's beverage brand strategy. In consideration for the acquisition, the Company paid a total purchase price of $22,979 in cash, which was subject to certain customary post-closing working capital adjustments.

The table below summarizes the fair value of the assets acquired and the liabilities assumed for the Craft Acquisition II at the effective acquisition date as follows:

---

| | |
|:---|:---|
|  | ***Amount*** |
| **Consideration** |  |
| Cash consideration | $22979 |
| **Net assets acquired** |  |
| **Current assets** |  |
| Cash and cash equivalents | 4869 |
| Accounts receivable | 1993 |
| Inventory | 6844 |
| Prepaids and other current assets | 185 |
| **Long-term assets** |  |
| Capital assets | 20916 |
| Finance lease, right-of-use assets | 1869 |
| Operating lease, right-of-use assets | 1884 |
| **Total assets** | 38560 |
| **Current liabilities** |  |
| Accounts payable and accrued liabilities | 11828 |
| Current portion of finance lease liabilities | 354 |
| Current portion of operating lease liabilities | 564 |
| **Long - term liabilities** |  |
| Finance lease liabilities | 1515 |
| Operating lease liabilities | 1320 |
| **Total liabilities** | 15581 |
| **Total net assets acquired** | 22979 |

---

In the event that the Craft Acquisition II had occurred on *June 1, 2024,* the Company would have had, on an unaudited proforma basis, additional net revenue of approximately $nil and $nil for the *three* and *six* months ended *November 30, 2025* and approximately $nil and $13,700 for the *three* and *six* months ended *November 30, 2024,* respectively, and its consolidated net loss and comprehensive net loss would have increased by approximately $nil and $nil for the *three* and *six* months ended *November 30, 2025* and approximately $nil and $4,000 for the *three* and *six* months ended *November 30, 2024,* respectively. This unaudited pro forma financial information does *not* reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition II.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9

------

**Note *8.* Long term investments**

Long term investments consisted of the following:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| Equity investments measured at fair value | $5233 | $1972 |
| Equity investments under measurement alternative | 8160 | 8160 |
| Total | $13393 | $10132 |

---

As of *November 30, 2025* and *May 31, 2025*, included within equity investment under measurement alternative is an option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization valued at $8,160. See Note *24* (Financial risk management and financial instruments).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

**Note *9.* Bank indebtedness**

Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000, which bears interest at the lender's prime rate plus 75 basis points. As of *November 30, 2025*, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on certain real property located at *265* Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has two operating lines of credit in the amounts of €7,000 and €500. These lines bear interest at Euro Short-Term Rate ("ESTR") plus 2.50% and Euro Interbank Offered Rate ("EURIBOR") plus 4.00%, respectively. As of *November 30, 2025*, a total of €7,386 ($8,567) was drawn down from the total available credit of €7,500. The operating line of credit for €7,000 is secured by an interest in the inventory of CC Pharma GmbH as well as the Densborn, Germany production facility and underlying real property. The operating line of credit for €500 is unsecured.

On *July 25, 2025,* the Company's wholly-owned subsidiary, American Beverage Crafts Group Inc. ("ABC Group"), formerly known as Four Twenty Corporation, finalized its *fifth* amendment (the "Amendment") to that certain Credit Agreement dated as of *June 30, 2023 (*the "ABC Group Credit Agreement") by and among the Borrower, Bank of America, N.A., in its capacity as Administrative Agent, and certain other guarantors and lenders party thereto. Specifically, the Amendment amended and restated the ABC Group Credit Agreement to provide for the contribution of the Manitoba Harvest entities' equity to the Borrower as additional collateral. Additionally, the Amendment added financial covenants for (i) minimum consolidated trailing-*twelve*-months EBITDA for each of the *four* quarters, beginning *May 31, 2025* and (ii) minimum liquidity. ABC Group has a revolving credit facility of $25,000, which bears interest at SOFR plus an applicable margin. As of *November 30, 2025*, the Company has drawn $nil on the revolving line of credit under the ABC Group Credit Agreement.

**Note *10.* Accounts payable and accrued liabilities**

Accounts payable and accrued liabilities are comprised of:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| Trade payables | $114496 | $107348 |
| Accrued liabilities | 82519 | 103260 |
| Litigation accruals | 12013 | 12431 |
| Accrued payroll and employment related taxes | 5151 | 1436 |
| Income taxes payable | 1905 | 58 |
| Accrued interest | 3873 | 4193 |
| Sales taxes payable | 6465 | 6596 |
| Total | $226422 | $235322 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

**Note *11.* Long-term debt** 

The following table sets forth the net carrying amount of long-term debt instruments:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| Term loan - C$53,000 - Canadian prime plus an applicable margin, 3-year term, with a 10-year amortization, repayable in equal quarterly payments due in February 2028 | $36720 | $38690 |
| Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$181 including interest, due in July 2033 | 10788 | 11501 |
| Term loan - C$25,000 - Canadian prime plus 1.00%, compounded monthly, 5-year term, with a 15-year amortization, repayable in equal monthly installments of C$196 including interest, due in July 2033 | 8772 | 9354 |
| Term loan - C$1,250 - Canadian prime plus 1.50%, 5-year term, with a 10-year amortization, repayable in equal monthly installments of C$12 including interest, due in August 2026 | 90 | 157 |
| Mortgage payable - C$3,750 - Canadian prime plus 1.50%, 5-year term, with a 20-year amortization, repayable in equal monthly installments of C$23 including interest, due in August 2026 | 1930 | 2020 |
| Term loan - €3,500 - at 4.59%, 5-year term, repayable in monthly installments of €52 plus interest, due in August 2028 | 2216 | 2546 |
| Mortgage payable - $22,635 - EURIBOR rate plus 1.5%, 10-year term, repayable in monthly installments of $57 to $69, due in October 2030 | 19047 | 19418 |
| Term loan - $90,000 - SOFR plus an applicable margin, 5-year term, repayable in quarterly installments of $875 to $2,250 due in June 2028 | 77063 | 80438 |
| Carrying amount of long-term debt | 156626 | 164124 |
| Unamortized financing fees | (998) | (864) |
| Net carrying amount | 155628 | 163260 |
| Less principal portion included in current liabilities | (16889) | (14767) |
| Total non-current portion of long-term debt | $138739 | $148493 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *12*

------

**Note *12.* Convertible debentures payable**

The following table sets forth the net carrying amount of the convertible debentures payable:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| 5.20% Convertible Notes ("TLRY 27") | $86255 | $86428 |
| Deduct - current portion |  |  |
| Total convertible debentures payable, non current portion | $86255 | $86428 |

---

*TLRY *27* Notes*

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| 5.20% Contractual debenture | $172500 | $172500 |
| Debt settlement | (72500) | (67500) |
| Unamortized discount | (13745) | (18572) |
| Net carrying amount | $86255 | $86428 |

---

The TLRY *27* convertible debentures were issued on *May 30, 2023* and on *June 9, 2023* by way of overallotment, in the principal amount of $172,500 (the "TLRY *27* Notes"). The TLRY *27* Notes bear interest at a rate of 5.20% per annum, payable semi-annually in arrears on *June 15* and *December 15* of each year, and mature on *June 15, 2027,* unless earlier converted. The TLRY *27* Notes are Tilray's general unsecured obligations and rank senior in right of payment to all of Tilray's indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray's unsecured indebtedness that is *not* so subordinated, effectively junior in right of payment to any of Tilray's secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray's current or future subsidiaries. Noteholders have the right to convert their TLRY *27* Notes into shares of Tilray's Common Stock at their option, at any time, until the close of business on the *second* scheduled trading day immediately before *June 15, 2027.* The initial conversion rate is approximately 37.66 shares per $1,000 principal amount of TLRY *27* Notes, which represents a conversion price of approximately $26.55 per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

During the *six* months ended *November 30, 2025,* the Company exchanged an aggregate $5,000 of its TLRY *27* Notes for cancellation, by issuing 1,259,182 shares of Common Stock and paying $6 in cash to settle accrued interest. Upon exchanging the TLRY *27* Notes, a portion of the settlement consideration was allocated to the equity component of the instrument and was recognized as a $1,158 reduction of additional paid-in capital in the Consolidated Statements of Stockholders' Equity. Additionally, this repurchase resulted in a gain of $495 which was recorded in other non-operating (losses) gains, net as shown in Note *23* (Non-operating income (expense)). Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by 120,969 shares which were then returned as Treasury Stock. As of *November 30, 2025* and *May 31, 2025*, a total of 2,231,884 and 2,343,478 shares remained outstanding under the share lending arrangement, respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on *December 2, 2025.* 

During the *three* and *six* months ended *November 30, 2025*, the Company recognized interest expense of $1,256 and $2,623 and accretion of amortized discount interest of $1,988 and $3,964 respectively. During the *three* and *six* months ended *November 30, 2024,* the Company recognized interest expense of $2,133 and $4,375 and accretion of amortized discount interest of $2,919 and $5,985 respectively.

As of *November 30, 2025*, there was $100,000 principal outstanding compared to $105,000 principal outstanding as of *May 31, 2025* under the TLRY *27* Notes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *13*

------

**Note *13.* Warrant liability**

Between *September 5, 2025* and *15, 2025,* certain holders elected to exercise an aggregate of 620,900 of the Company's issued and outstanding warrants in accordance with their terms. Pursuant to the exercise of such warrants, Tilray received $2,367 of cash consideration and delivered 620,900 shares of common stock to such holders. As of *November 30, 2025* and *May 31, 2025*, there were nil and 620,900 warrants outstanding respectively. Current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on *December 2, 2025.* 

**Note *14.* Stockholders' equity** 

*Issued and outstanding*

Pursuant to its Fifth Amended and Restated Certificate of Incorporation, the total number of shares that the Company is authorized to issue is 1,426,000,000 shares, of which 1,416,000,000 shares are Common Stock, and 10,000,000 shares of which are Preferred Stock (the "Preferred Stock"). As of *November 30, 2025*, the Company had issued and outstanding 116,522,600 shares of Common Stock, 321,391 shares of Treasury Stock (the "Treasury Stock") and no Preferred Stock. Historically, the Company has issued shares of its Common Stock in consideration for acquisitions and other strategic transactions, settlement of convertible notes, settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.

During the *six* months ended *November 30, 2025*, the Company issued the following shares of Common Stock:

a) 6,777,224 shares of Common Stock pursuant to its At-the-Market ("ATM") program, which generated gross proceeds of $76,643 and net proceeds of $73,056, after deducting $3,587 in commissions and other fees associated with these issuances.

b) 1,259,182 shares of Common Stock in the amount of $4,800 to exchange the aggregate principal of $5,000 of its TLRY *27* Notes for cancellation. Upon exchanging the TLRY *27* Notes, a portion of the settlement consideration was allocated to the equity component of the instrument and was recognized as a $1,158 reduction of additional paid-in capital. Following consummation of the exchange, the number of outstanding Borrowed Shares of Common Stock was reduced by approximately 120,969 shares which were then returned as Treasury Stock, see Note *12* (Convertible debentures payable).

c) 620,900 shares of Common Stock to settle exercised warrants.

d) 861,707 shares of Common Stock to settle dividends payable to the non-controlling shareholders of Aphria Diamond in the amount of $14,821.

e) 935,712 shares of Common Stock in connection with the exercise of previously awarded stock-based compensation awards, net of cancellations.

During the *six* months ended *November 30, 2025*, the Company granted 4,551,621 time-based Restricted Stock Units ("RSUs").

During the fiscal year ended *May 31, 2024,* the Company issued 756,615 performance-based RSUs. These RSUs were *not* considered granted for accounting purposes at the time of issuance, as the performance conditions had *not* yet been established or approved and *no* amounts have been recorded within the Consolidated Statement of Income (Loss). During the intervening period, from their initial issuance to the current quarter, the total number of performance-based RSUs was reduced to 744,117 due to attrition. During the *three* months ended *November 30, 2025,* the Company established and approved the relevant performance targets for the performance-based RSUs and consequently considered them granted for accounting purposes. In conjunction with this award, an additional component of these performance based grants are payable in cash or its equivalent in shares of Common Stock at the discretion of Company's Compensation Committee. Given the expected settlement in Common Stock, the fair value of these awards has also been recorded as stock-based compensation, with the corresponding liability reflected on the Statement of Financial Position. As a result, during the *three* months ended *November 30, 2025,* the Company began accruing the fair value of these awards over the remaining requisite service period.

The Company's total stock-based compensation expense incurred for the *three* and *six* months ended *November 30, 2025* was $12,283 and $17,335 compared to $7,237 and $14,154 for the *three* and *six* months ended *November 30, 2024,* respectively.

All current and prior year share amounts have been retrospectively adjusted to reflect the Reverse Stock Split, which became effective on *December 2, 2025.* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *14*

------

**Note *15.* Accumulated other comprehensive income (loss)**

Accumulated other comprehensive income (loss) is comprised of foreign currency translation gain (loss) as follows:

---

| | |
|:---|:---|
|  | ***Total*** |
|  | ***Foreign*** |
|  | ***currency*** |
|  | ***translation*** |
|  | ***gain (loss)*** |
| Balance May 31, 2024 | $(43499) |
| Other comprehensive income (loss) | 3622 |
| Balance August 31, 2024 | $(39877) |
| Other comprehensive income (loss) | (8080) |
| Balance November 30, 2024 | $(47957) |
| Balance May 31, 2025 | $(43063) |
| Other comprehensive income (loss) | (167) |
| Balance August 31, 2025 | $(43230) |
| Other comprehensive income (loss) | 3937 |
| Balance November 30, 2025 | $(39293) |

---

**Note *16.* Non-controlling interests** 

The following are majority-owned subsidiaries of the Company and the percentage of ownership interest maintained by the Company is set forth in the parenthetical: Enroot (75%), Aphria Diamond (51%), and Colcanna S.A.S. (90%).

The following table provides a summary of certain balance sheet information before intercompany eliminations relating to the above-referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest as of *November 30, 2025*:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | ***Aphria*** | ***ColCanna*** | ***November 30,*** |
|  | ***Enroot*** | ***Diamond*** | ***S.A.S.*** | ***2025*** |
| Current assets | $203 | $69005 | $3 | $69211 |
| Non-current assets |  | 108486 | 3761 | 112247 |
| Current liabilities | (4) | (124948) | (7030) | (131982) |
| Non-current liabilities |  | (31529) | (1440) | (32969) |
| Net assets | $199 | $21014 | $(4706) | $16507 |

---

The following table provides a summary of certain balance sheet information before intercompany eliminations relating to the above-referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest as of *May 31, 2025*:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **SH** | **CC Pharma** | **Aphria** | **ColCanna** | **May 31,** |
|  | **Acquisition** | **Nordic ApS** | **Diamond** | **S.A.S.** | **2025** |
| Current assets | $— | $— | $83390 | $20 | $83410 |
| Non-current assets |  |  | 114677 | 3348 | 118025 |
| Current liabilities |  |  | (126986) | (6953) | (133939) |
| Non-current liabilities |  |  | (31720) | (1442) | (33162) |
| Net assets | $— | $— | $39361 | $(5027) | $34334 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *15*

------

The following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest for the *six* months ended *November 30, 2025*:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  | ***Aphria*** | ***ColCanna*** | ***November 30,*** |
|  | ***Enroot*** | ***Diamond*** | ***S.A.S.*** | ***2025*** |
| Revenue | $4 | $31258 | $— | $31262 |
| Total expenses | 7 | 24762 | (736) | 24033 |
| Net (loss) income | (3) | 6496 | 736 | 7229 |
| Other comprehensive (loss) income |  | 1120 | (415) | 705 |
| Net comprehensive (loss) income | $(3) | $7616 | $321 | $7934 |
| Non-controlling interest % | 25% | 49% | 10% | *NA* |
| Comprehensive (loss) income attributable to NCI | (1) | 3732 | 32 | 3763 |
| Net comprehensive (loss) income attributable to NCI | $(1) | $3732 | $32 | $3763 |

---

The following table provides a summary of certain income statement information before intercompany eliminations relating to the above referenced majority-owned subsidiaries of the Company in which there was a non-controlling interest for the *six* months ended *November 30, 2024:*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | ***SH*** | ***CC Pharma*** | ***Aphria*** | ***ColCanna*** | ***November 30,*** |
|  | ***Acquisition*** | ***Nordic ApS*** | ***Diamond*** | ***S.A.S.*** | ***2024*** |
| Revenue | $— | $— | $36429 | $— | $36429 |
| Total expenses |  | 5 | 26919 | 793 | 27717 |
| Net (loss) income |  | (5) | 9510 | (793) | 8712 |
| Other comprehensive (loss) income |  | (1) | (796) | 434 | (363) |
| Net comprehensive (loss) income | $— | $(6) | $8714 | $(359) | $8349 |
| Non-controlling interest % | 32% | 25% | 49% | 10% | *NA* |
| Comprehensive (loss) income attributable to NCI |  | (2) | 4270 | (36) | 4232 |
| Net comprehensive (loss) income attributable to NCI | $— | $(2) | $4270 | $(36) | $4232 |

---

**Note *17.* Income taxes**

The determination of the Company's overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases, and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock compensation, and the Company's change in income in each jurisdiction all affect the overall effective tax rate. It is the Company's practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax expense of $3,546 and $1,261 for the *three* and *six* months ended *November 30, 2025*, and $2,036 and $2,922 for the *three* and *six* months ended *November 30, 2024.* The income tax expense in the current period varies from the US statutory income tax rate and prior year period primarily due to the geographical mix of earnings and losses with *no* tax benefit resulting from valuation allowances in certain jurisdictions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *16*

------

**Note *18.* Commitments and contingencies**

*Purchase and other commitments* 

The Company has financial commitments on long-term debt, refer to Note *11* (Long-term debt), convertible notes, refer to Note *12* (Convertible debentures payable), material purchase commitments inclusive of multi-period sponsorship rights and construction commitments as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | ***Total*** | ***2026*** | ***2027*** | ***2028*** | ***2029*** | ***Thereafter*** |
| Long-term debt repayment | $156626 | $16889 | $13624 | $94715 | $3619 | $27779 |
| Convertible debentures payable | 100000 |  |  | 100000 |  |  |
| Material purchase obligations | 63319 | 33363 | 28261 | 615 | 530 | 550 |
| Construction commitments | 1209 | 1209 |  |  |  |  |
| Total | $321154 | $51461 | $41885 | $195330 | $4149 | $28329 |

---

*Legal proceedings*

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves *may* be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is *not* probable or the amount of loss is *not* estimable, we do *not* accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are *not* expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, *may* be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

There have been *no* material changes in the legal proceedings since our Annual Report on Form *10*-K for the fiscal year ended *May 31, 2025*.

**Summary of litigation accruals** 

As described in Note *10* (Accounts payable and accrued liabilities), the total estimated litigation expense accrual included in accrued liabilities as of *November 30, 2025* and *May 31, 2025* was $12,013 and $12,431, respectively. This estimated accrual is intended to cover various ongoing litigation matters with probable losses that can be reasonably estimated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *17*

------

**Note *19.* Net revenue**

The Company reports Net revenue in four reporting segments: beverage, cannabis, distribution, and wellness. Net revenue for the *three* and *six* months ended *November 30, 2025* and *three* and *six* months ended *November 30, 2024* were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Beverage revenue | $53552 | $66861 | $112064 | $126024 |
| Beverage excise taxes | (3469) | (3780) | (6242) | (6971) |
| Net beverage revenue | 50083 | 63081 | 105822 | 119053 |
| Cannabis revenue | 90208 | 87208 | 177943 | 168402 |
| Cannabis excise taxes | (22676) | (21556) | (45900) | (41501) |
| Net cannabis revenue | 67532 | 65652 | 132043 | 126901 |
| Distribution revenue | 85316 | 67611 | 159323 | 135682 |
| Wellness revenue | 14576 | 14606 | 29820 | 29358 |
| Total | $217507 | $210950 | $427008 | $410994 |

---

**Note *20.* Cost of goods sold**

The Company reports Cost of goods sold in four reporting segments: beverage, cannabis, distribution, and wellness. Cost of goods sold for the *three* and *six* months ended *November 30, 2025* and *three* and *six* months ended *November 30, 2024* were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Beverage costs | 34351 | 37925 | 68764 | $70975 |
| Cannabis costs | 41398 | 42475 | 82639 | 79529 |
| Distribution costs | 74334 | 59207 | 140342 | 119345 |
| Wellness costs | 9927 | 10123 | 20297 | 20219 |
| Total | $160010 | $149730 | $312042 | $290068 |

---

**Note *21.* General and administrative expenses**

General and administrative expenses for the *three* and *six* months ended *November 30, 2025* and *three* and *six* months ended *November 30, 2024* were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Salaries and wages | $24764 | 22726 | $46500 | $44293 |
| Office and general | 8284 | 9458 | 16981 | 18718 |
| Stock-based compensation | 12283 | 7237 | 17335 | 14154 |
| Insurance | 2456 | 3155 | 4849 | 5610 |
| Professional fees | 1034 | 1126 | 2252 | 2304 |
| Gain on sale of capital assets | (134) | (505) | (375) | (531) |
| Travel and accommodation | 1292 | 1754 | 2604 | 3247 |
| Rent | 1196 | 1046 | 2082 | 2315 |
| Total | $51175 | $45997 | $92228 | $90110 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *18*

------

**Note *22.* Restructuring charges**

In connection with the integration of certain acquisitions and strategic transactions, the Company has incurred restructuring and exit costs in the amount of $965 and $1,834 for the *three* and *six* months ended *November 30, 2025*, compared to $6,869 and $11,116 for the *three* and *six* months ended *November 30, 2024.* All restructuring plans are approved at the executive level, and their associated expenses are recognized in the period in which the plan is committed or otherwise incurred.

Within the Cannabis segment, during the *six* months ended *November 30, 2025,* the Company incurred restructuring-related expenses totaling $1,834. These charges included $670 associated with the restructuring of the Quebec facility to transition from vegetable cultivation to cannabis cultivation in response to increased global cannabis demand, $843 related to employee termination severance and benefits associated with the reorganization of the Canadian cannabis commercial function, and $177 related to the wind-down of certain non-operating entities. Additionally, the Company recognized $144 related to its Fort Collins, CO partially vacant warehouse recorded under assets held of sale. See Note *3* (capital assets).

During the fiscal year ended *May 31, 2025,* the Company accrued $8,500 of restructuring charges related to the closure of Hop Valley and other Project *420* initiatives within the Beverage segment, of which $4,570 was recognized in the *six* months ended *November 30, 2025* thereby, reducing the accrual to $3,930.

**Note *23.* Non-operating income (expense), net**

Non-operating income (expense), net for the *three* and *six* months ended *November 30, 2025* and *three* and *six* months ended *November 30, 2024* were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Change in fair value of warrant liability | $175 | $862 | $(3495) | $1558 |
| Foreign exchange gain (loss) | (10327) | (33797) | (3399) | (21916) |
| (Loss) gain on long-term investments | (345) | (27) | (306) | (66) |
| Unrealized loss on digital assets | (164) |  | (172) |  |
| Other non-operating (losses) gains, net | (1649) | (293) | (1106) | (185) |
| Total | $(12310) | $(33255) | $(8478) | $(20609) |

---

The other non-operating losses (gains), net for the *three* and *six* months ended *November 30, 2025*, were losses of $1,649 and $1,106 which was mainly comprised of a loss of $1,800 on the change in fair value of assets held for sale related to the Fort Collins, CO partially vacant warehouse, as described in Note *3* (capital assets), offset by a gain of $495 resulting from the exchange transaction of the TLRY *27* Note, as described in Note *12* (Convertible debentures payable).

**Note *24.* Financial risk management and financial instruments**

**Financial instruments**

The Company's classification of its financial instruments is described in Note *3* (Significant accounting policies) in the Notes to our Annual Financial Statements.

The carrying values of marketable securities, accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

On *November 30, 2025* and *May 31, 2025*, the Company had long-term debt of $2,216 and $2,546, respectively, and the principal portion of convertible debentures payable of $100,000 and $105,000, respectively, subject to fixed interest rates. The Company's long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *19*

------

The following tables present information about the Company's assets and liabilities that are measured at fair value on a recurring basis as of *November 30, 2025* and *May 31, 2025* and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | ***November 30,*** |
|  | ***Level 1*** | ***Level 2*** | ***Level 3*** | ***2025*** |
| Financial assets |  |  |  |  |
| Cash and cash equivalents | $246703 | $— | $— | $246703 |
| Marketable securities | 44848 |  |  | 44848 |
| Equity investments measured at fair value | 4229 | 1004 | 8160 | 13393 |
| Digital assets | 828 |  |  | 828 |
| Total recurring fair value measurements | $296608 | $1004 | $8160 | $305772 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  |  |  |  | ***May 31,*** |
|  | ***Level 1*** | ***Level 2*** | ***Level 3*** | ***2025*** |
| Financial assets |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $221666 | $— | $— | $221666 |
| Marketable securities | 34697 |  |  | 34697 |
| &nbsp;&nbsp;&nbsp; Equity investments measured at fair value | 909 | 1063 | 8160 | 10132 |
| Financial liabilities |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Warrant liability |  |  | (1092) | (1092) |
| Contingent consideration |  |  | (15000) | (15000) |
| Total recurring fair value measurements | $257272 | $1063 | $(7932) | $250403 |

---

The Company's financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, digital assets, acquisition-related contingent consideration, and warrant liability.

During the *six* months ended *November 30, 2025*, the Company purchased 9.16 units of Bitcoin. Digital assets recorded at fair value have quoted prices in active markets for identical assets and are classified as Level *1.* The following table presents the Company's digital asset holdings as of *November 30, 2025*:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***Quantity*** | ***Cost Basis*** | ***Fair Value*** | ***Cumulative Unrealized Gain (Loss)*** |
| Bitcoin | 9.16 | $1000 | $828 | $(172) |
| Total digital assets | 9.16 | $1000 | $828 | $(172) |

---

Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level *1.* The Company classified securities with observable inputs as Level *2* and without a quoted market price as Level *3.*

A portion of the consideration to be paid in connection with the Company's acquisition of Montauk Brewing Company ("Montauk") is contingent upon the achievement of certain financial measures as of *December 31, 2025.* If achieved, such contingent consideration is payable in cash. During the *six* months ended *November 30, 2025*, the contingent consideration amount was reassessed and was estimated by applying a probability of achievement of *0%* on the *$15,000* sales earn-out component and 0% on the remaining criteria. The Montauk contingent earn-out is *no* longer expected to be achieved based on Montauk's current operating results, and as such resulted in a corresponding change in fair value of $15,000 for the contingent consideration liability recognized. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level *3.*

The balances of assets and liabilities categorized within Level *3* of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows for the period ended *November 30, 2025*:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *20*

------

---

| | | | |
|:---|:---|:---|:---|
|  | ***Equity*** | ***Warrant*** | ***Contingent*** |
|  | ***Investments*** | ***Liability*** | ***Consideration*** |
| Balance, May 31, 2025 | $8160 | $(1092) | $(15000) |
| Unrealized gain (loss) on fair value |  | (3495) | 15000 |
| Instruments exercised |  | 4587 |  |
| Balance, November 30, 2025 | $8160 | $— | $— |

---

The balances of assets and liabilities categorized within Level *3* of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows for the period ended *November 30, 2024:*

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | ***APHA 24*** |
|  | ***Convertible*** | ***Equity*** | ***Warrant*** | ***Contingent*** | ***Convertible*** |
|  | ***notes receivable*** | ***Investments*** | ***Liability*** | ***Consideration*** | ***Debt*** |
| Balance, May 31, 2024 | $32000 | $5500 | $(3253) | $(15000) | $(330) |
| Additions/(Repayments) |  |  |  |  | 330 |
| Unrealized gain (loss) on fair value |  |  | 1558 |  |  |
| Balance, November 30, 2024 | $32000 | $5500 | $(1695) | $(15000) | $— |

---

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:

---

| | | | |
|:---|:---|:---|:---|
|  |  | ***Significant*** |  |
|  | ***Valuation*** | ***unobservable*** |  |
| **Financial asset / financial liability** | ***technique*** | ***input*** | ***Inputs*** |
| Contingent consideration | *Discounted cash flows* | *Probability of achievement* | 0% |
| Equity investments | *Discounted cash flows* | *Probability of achievement* | 70% |

---

*<u>Items measured at fair value on a non-recurring basis</u>*

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been *no* changes to the Company's capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

**Note *25.* Segment reporting**

Our Company's Chief Operating Decision Maker ("CODM") is the Chairman of the Board of Directors and Chief Executive Officer. The CODM uses segment gross profit for the purpose of resource allocation, assessment of segment performance against determined targets, and in deciding whether to implement cost saving targets. The Company operates in four segments. *1*) cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, *2*) beverage operations, which encompasses the production, marketing and sale of beverage products, *3*) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers, and *4*) wellness products, which encompasses wellness and better-for-you foods and beverages. This structure is in line with how our CODM assesses our performance and allocates resources.

Operating segments have *not* been aggregated and *no* asset information is provided for the segments because the Company's CODM does *not* receive asset information by segment on a regular basis.

The following tables reconcile the Company's segment gross profit to consolidated U.S. GAAP results:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *21*

------

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| **Beverage** |  |  |  |  |
| Net beverage revenue | $50083 | $63081 | $105822 | $119053 |
| Beverage costs | 34351 | 37925 | 68764 | 70975 |
| Beverage gross profit | 15732 | 25156 | 37058 | 48078 |
| **Cannabis** |  |  |  |  |
| Net cannabis revenue | 67532 | 65652 | 132043 | 126901 |
| Cannabis costs | 41398 | 42475 | 82639 | 79529 |
| Cannabis gross profit | 26134 | 23177 | 49404 | 47372 |
| **Distribution** |  |  |  |  |
| Distribution revenue | 85316 | 67611 | 159323 | 135682 |
| Distribution costs | 74334 | 59207 | 140342 | 119345 |
| Distribution gross profit | 10982 | 8404 | 18981 | 16337 |
| **Wellness** |  |  |  |  |
| Wellness revenue | 14576 | 14606 | 29820 | 29358 |
| Wellness costs | 9927 | 10123 | 20297 | 20219 |
| Wellness gross profit | 4649 | 4483 | 9523 | $9139 |
| **Total** |  |  |  |  |
| Total revenue | 217507 | 210950 | 427008 | 410994 |
| Total costs | 160010 | 149730 | 312042 | 290068 |
| Total gross profit | $57497 | $61220 | $114966 | $120926 |

---

Segment costs are comprised of cost of goods sold, which include product costs, salaries and an allocation of overhead costs.

The following table reconciles the total segment gross profit to the Company's consolidated totals:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Gross profit | $57497 | $61220 | $114966 | $120926 |
| Operating expenses: |  |  |  |  |
| General and administrative | 51175 | 45997 | 92228 | 90110 |
| Selling | 11781 | 16162 | 24704 | 27852 |
| Amortization | 4358 | 22927 | 8287 | 44731 |
| Marketing and promotion | 9981 | 9720 | 20136 | 21286 |
| Research and development | 78 | 60 | 119 | 165 |
| Change in fair value of contingent consideration |  |  | (15000) |  |
| Litigation costs, net of recoveries | 869 | 901 | 1876 | 2496 |
| Restructuring costs | 965 | 6869 | 1834 | 11116 |
| Transaction costs (income), net | 569 | 802 | 969 | 1958 |
| Total operating expenses | 79776 | 103438 | 135153 | 199714 |
| Operating loss | (22279) | (42218) | (20187) | (78788) |
| Interest expense, net | (5374) | (7766) | (12070) | (17608) |
| Non-operating income (expense), net | (12310) | (33255) | (8478) | (20609) |
| Loss before income taxes | (39963) | (83239) | (40735) | (117005) |
| Income tax expense (recovery), net | 3546 | 2036 | 1261 | 2922 |
| Net loss | $(43509) | $(85275) | $(41996) | $(119927) |

---

Channels of Cannabis revenue were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| Revenue from Canadian medical cannabis | $6234 | $6673 | $12380 | $12934 |
| Revenue from Canadian adult-use cannabis | 62448 | 59077 | 126515 | 116312 |
| Revenue from wholesale cannabis | 1346 | 6593 | 5501 | 12100 |
| Revenue from international cannabis | 20180 | 14865 | 33547 | 27056 |
| Less excise taxes | (22676) | (21556) | (45900) | (41501) |
| Total | $67532 | $65652 | $132043 | $126901 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *22*

------

Geographic net revenue:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***For the three months ended*** | ***For the three months ended*** | ***For the six months ended*** | ***For the six months ended*** |
|  | ***November 30,*** | ***November 30,*** | ***November 30,*** | ***November 30,*** |
|  | ***2025*** | ***2024*** | ***2025*** | ***2024*** |
| USA | $57838 | $71753 | $121799 | $135633 |
| Canada | 54173 | 56720 | 112340 | 112625 |
| EMEA | 103155 | 79254 | 188408 | 156926 |
| Rest of World | 2341 | 3223 | 4461 | 5810 |
| Total | $217507 | $210950 | $427008 | $410994 |

---

Geographic capital assets:

---

| | | |
|:---|:---|:---|
|  | ***November 30,*** | ***May 31,*** |
|  | ***2025*** | ***2025*** |
| USA | $193897 | $200003 |
| Canada | 253515 | 267458 |
| EMEA | 98446 | 97371 |
| Rest of World | 4243 | 3601 |
| Total | $550101 | $568433 |

---

Major customers are defined as customers that are materially significant to the Company's annual revenues. For the *three* and *six* months ended *November 30, 2025* and *2024*, there were no major customers representing a material contribution to our quarterly revenues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

------

**Item 2. Management**'**s Discussion and Analysis of Financial Condition and Results of Operations.**

*This Management*'*s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Unaudited Interim Consolidated Financial Statements and the related Notes thereto for the three month period ended November 30, 2025 contained in this Quarterly Report on Form 10-Q (*"*Form 10-Q*"*) and the Audited Consolidated Financial Statements and the related Notes thereto contained in our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, as well as in conjunction with the sections entitled* "*Item 1A. Risk Factors*" *and* "*Item 7. Management*'*s Discussion and Analysis of Financial Condition and Results of Operations*" *in our Annual Report on Form 10-K for the fiscal year ended May 31, 2025 and in the section entitled "Item 1A. Risk Factors" in this Form 10-Q. Forward looking statements in this Form 10-Q are qualified by the cautionary statement included in this Form 10-Q under the sub-heading* "*Cautionary Note Regarding Forward-Looking Statements*" *in the introduction of this Form 10-Q.* 

**Company Overview** 

Tilray Brands, Inc., a Delaware corporation (collectively, along with its subsidiaries, the "Company", "Tilray", "we", "us" and "our"), is a leading global lifestyle consumer products company, which was incorporated on January 24, 2018 and is headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness, and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy, wellness and create memorable experiences.

Our overall strategy is to leverage our brands, infrastructure, expertise and capabilities to drive revenue growth in the industries in which we compete, achieve industry-leading profitability and build sustainable, long-term shareholder value. In order to ensure the long-term sustainable growth of our Company, we continue to focus on developing strong capabilities in data analytics and consumer insights, drive category management leadership and assess opportunities for the introduction of new categories, products and entries into new geographies. In addition, we are relentlessly focused on managing our cost structure and expenses in order to maintain our strong financial position. Finally, our experienced leadership team provides a strong foundation to accelerate our growth. Our management team is complemented by experienced operators, cannabis industry experts, veteran beer and beverage industry leaders and leaders that are well-established in wellness and better-for-you products, all of whom apply an innovative and consumer-centric approach to our businesses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24

------

**Trends and Other Factors Affecting Our Business** 

***Beverage market trends:***

Within the beverage category, we expect the following key trends to continue to shape the near-term outlook in this segment:

*Beverage Distribution*. In furtherance of our strategic vision, we remain focused on enhancing our relevance within home markets with mission critical SKUs, focusing on our core brands in their core markets and on driving growth of our highest margin SKUs within these brands. Through targeted efforts, we continue to strategically optimize our price/pack/channel architecture and drive distribution to continue to execute against our craft beer strategy, streamlining our business, enhancing our relevance and focusing resources on our core markets. The 2025 Spring retail product resets demonstrated improvements in the distribution of our core brands and key innovation initiatives, including Shock Top, Runner's High non-alcoholic, and SweetWater Brewing's newly launched Day Trip and Dive Beer amongst others. We have started to see the impact of these gains throughout fiscal year 2026. <br>

*Innovation*. In the United States, we have been closely monitoring consumer beverage trends, which have included consumers drinking less beverage alcohol products and, when consuming alcoholic beverages, the increasing demand for ready-to-drink cocktail options. To address these trends, we have engaged in strategic innovation based on data analysis, consumer insights, and portfolio diversification into alternative beverage options. For the consumer seeking to reduce their beverage alcohol consumption, our recent innovations include launching a portfolio of Non-Alcoholic craft beer, sparkling waters under our Liquid Love brand, and clean label energy drinks fortified with vitamins. Our other innovative products include Hemp Derived Delta-9 (HD-D9) beverages. Although new U.S. federal legislation was recently enacted that will restrict the production and sale of our HD-D9 beverages beginning in November 2026, we believe that new regulations could evolve prior to that date to permit continued sales of HD-D9 beverages under the recent executive order directing the U.S. rescheduling of cannabis products. These strategic innovations underscore our commitment to offering high-quality options across a diverse range of beverage categories, positioning us for sustained growth by meeting consumer demand and differentiation in the competitive beverage segment.<br>

*Brew Pubs*. We currently operate 17 brew pubs, including our Breckenridge Distillery restaurant and tasting room, in geographic regions across the U.S. and core markets for the associated craft brands. An important part of our strategic plan for our craft beer business centers on the role that brew pubs play in promoting and showcasing the distinct, regional positioning of our various craft beer brands. They provide our consumers with a venue in which to connect with others and have an immersive brand experience which serves to enhance brand loyalty and drive immediate and long-term revenue growth. We also believe that our brew pub strategy fuels trial and innovation by allowing us to curate unique small batch product offerings in targeted test markets. <br>

In the spirits category, Breckenridge Distillery combines premium craftsmanship, award-winning quality, and experiential tourism appeal, reinforcing its niche as a lifestyle-driven spirits brand. The distillery has earned multiple prestigious accolades across Whiskey, Gin, and Vodka, including three Icons of Whisky awards, ten Best American Blended Whiskey honors at the World Whiskies Awards, and recognition as Colorado Distillery of the Year. Recent achievements include Breckenridge Reserve Port Cask Finish being named the World's Best Finished Bourbon at the 2024 World Whiskies Awards. Breckenridge Distillery products are available in all 50 states, with continued planned expansion and product innovations. Recent launches include Mock One – a non-alcoholic spirits line, Mountain Shot – flavored whiskey in convenient pouches, and Casa Breck Tequila, all underscoring our commitment to innovation and evolving consumer preferences. Despite prevailing challenges within the overall spirits market, we believe our focus on whiskey—a resilient segment—combined with our award-winning portfolio and innovative product introductions, positions Breckenridge Distillery for sustained growth and enhanced market presence.

***Canadian cannabis market trends:***

The cannabis industry in Canada continues to evolve given how nascent the industry is with federal legalization of adult-use cannabis occurring just over five years ago. Through analysis of the current market conditions, the following key trends have emerged and are anticipated to influence the near-term future in the Canadian cannabis industry:

*Market share*. During the quarter, Tilray continued to lead the Canadian market with the highest cannabis revenue in Canada. Additionally, during the quarter, we experienced a marginal decrease in market share in Canada from 9.4% to 9.3% from the immediately preceding quarter as reported by Hifyre data for all provinces, excluding Quebec where Weedcrawler was deemed more accurate. The current period decrease in market share reflects our strength in flower and non-infused pre-roll categories which was offset by our lower participation in specific categories experiencing the most price compression. Additionally, we continue to enhance our global supply chain and increase our cultivation footprint to support the growing demand for our product in both Canadian and international cannabis markets. In the meantime, we continue to opportunistically redirect certain inventories to international cannabis markets, which is expected to generate higher margin sales.<br>

*Price compression.* Historical price compression in specific categories is expected to persist in the market, intensified by fierce competition among the approximately 1,000 Licensed Producers in Canada. The fixed impact of excise per gram, notwithstanding the decline in average selling prices, further compounds these challenges, and has promoted ongoing industry lobbying efforts. <br>

***International cannabis trends:***

We are a global leader in the development, production, distribution, marketing and sale of pharmaceutical-grade medical cannabis products. The cannabis industry in Europe is still in its early stages of development and countries within Europe are at different stages of medical and adult-use cannabis legalization. The most meaningful progress to date has been the legalization and regulation of cannabis for medical purposes, which has now taken place in more than 19 countries representing a population of more than 477 million people (Germany, UK, Italy, Poland, Netherlands, Czech Republic, Greece, Portugal, Austria, Switzerland, Denmark, Croatia, Malta, Luxembourg, Ukraine, Sweden, Norway, Türkiye, Ireland, and Israel). Beyond this, some countries have expressed a clear political ambition to legalize adult-use cannabis (Portugal and Luxembourg), some are engaging in experiments for adult-use legalization (Germany, Netherlands, Malta, Czech Republic and Switzerland) and some are debating regulations for cannabinoid-based medicine (France and Spain). In Europe, we believe that, despite continuing recessionary economic conditions, political uncertainty in various countries and the continuing Russian conflict with Ukraine, cannabis legalization (both medicinal and adult-use) will continue to gain traction albeit more slowly than originally expected. This is evidenced by the cannabis regulations in Germany adopted on April 1, 2024, which we believe will serve as a catalyst for continued changes in drug policy throughout Europe. Outside of Europe and North America, the cannabis industry is also in its early stages of development with Australia representing one of the larger markets and with some Latin American countries also growing their respective medical cannabis markets, such as Argentina, Panama, Colombia and Brazil.

We continue to believe that Tilray remains uniquely well-positioned to maintain and gain significant market share in the markets in which we participate. We benefit from our end-to-end vertically-integrated infrastructure and well-placed investments, which are comprised of two EU-GMP cultivation facilities located in Portugal and Germany; our fully owned route-to-market encompassing sales, marketing and distribution infrastructure in Germany, Australia and Italy; a network of leading distributors who we work with in the various other countries in which we participate; and, our extensive genetics portfolio and demonstrated commitment and expertise related to the cultivation and production of high-quality, safe cannabis products. Tilray's International business also benefits from the depth and breadth of knowledge, experience, relationships and infrastructure we have gleaned from our leading participation and investment into the Canadian medical and adult-use markets. Tilray is proudly pioneering the effort to further understand the therapeutic value of cannabis through the guidance of its independent Medical Advisory board and through partnerships with leading research institutions globally, Tilray is currently supporting clinical trials around the world studying the efficacy of cannabis in treading various indications. We believe that these assets and attributes, combined with our ability to navigate complex regulatory environments, will continue to drive our leadership in international medical markets and allow us to successfully enter new markets as they adopt medical cannabis and potentially adult-use regulations and may also serve to support a potential U.S. participation.

*Germany*. Today, Germany remains the largest medical cannabis market in Europe.

We continue to believe that Tilray is well-positioned in Germany, especially considering the enactment of MedCanG and given that we are one of only three manufacturers of medical cannabis in Germany since our wholly owned subsidiary, Aphria RX, was awarded the first license for the cultivation of medical cannabis in Germany by the BfArM under the liberalized regime. Said license will improve our ability to meet the needs of patients and provide cannabis of the utmost quality and enhanced availability to a broader market.

As the market continues to mature, we have seen increased demands and differentiation specifically with medical cannabis flowers. In response, we have launched Redecan and Good Supply brands and related medical cannabis products, which provides the patient with a segmented portfolio of products while we continue to deliver on the trust, safety and consistency that has become expected from our Tilray Medical brand.

*Poland*. In Poland, cannabis was legalized for medical use in 2018 and is prescribed to patients by a physician and dispensed by pharmacies. Today, all doctors in Poland are allowed to prescribe medical cannabis and it is a self-pay market as medical cannabis is not refundable by the Polish health service. Tilray is a leading supplier of medical cannabis in Poland through our network of distributor partnerships. We predominantly supply the market with whole flower medical cannabis products.

*United Kingdom*. Since November 2018, doctors in the UK have been able to prescribe medical cannabis for medicinal use for patients with medical conditions that had failed to respond to first-line medications. The market today is predominantly all self-pay and prescriptions are facilitated by private clinics. Today, we supply the UK market with mainly whole flower products from both the Tilray Medical and Broken Coast brands through our distributor partners with sights on growing our portfolio to extracts and other formats.

*Ireland.* In June 2019, the Minister for Health signed legislation allowing for the operation of the Medical Cannabis Access Programme ("MCAP") on a pilot basis for five years. The MCAP allows a medical consultant to prescribe a cannabis-based treatment for a narrow set of specified medical conditions, where the patient has failed to respond to standard treatment. Reimbursement is available for products which have received the appropriate approvals. Tilray was one of the first players to enter the Irish market and is one of a few suppliers which has received approval for its products to be prescribed and to have been granted reimbursement status. Today, we supply our approved extract product to Ireland through our distribution partner.

*Italy*. In May 2023, Tilray Medical received authorization from Italy's Ministry of Health to distribute three new medical cannabis compounds. These medical cannabis compounds are distributed by FL Group, our wholly-owned subsidiary, to pharmacies across Italy. With FL Group, we have an established broad national pharmaceutical distribution network in Italy, where medical cannabis is prescribed by doctors and reimbursed by the healthcare system to eligible patients. In 2025, Tilray has received additional cannabis flower and extract product authorizations and has formed a strategic partnership with Molteni Farmaceutici with the commitment to broaden the availability of Tilray Medical products for patients across Italy.

*Australia*. In 2016, the Australian Government legalized medicinal cannabis, which is regulated by the Therapeutic Goods Administration. Medical cannabis is prescribed by a doctor but there is no coverage under the Pharmaceutical Benefits Scheme. Tilray Medical supplies the market with wide portfolio of medical cannabis extracts as well as whole flower products. As the market continues to mature, we have seen increased demands and differentiation specifically with medical cannabis flowers. In response, we launched the Broken Coast, Redecan and Good Supply brands and products, which provides the patient with a segmented portfolio of products while we continue to deliver on the trust, safety and consistency that has become expected from our Tilray Medical brand.

*Luxembourg*. Luxembourg established its medical cannabis framework in 2018, with the national program operational since February 2019. Medical cannabis is tightly regulated, accessible only through trained physicians and dispensed exclusively via hospital pharmacies. Prescriptions are limited to patients with defined, severe medical conditions, and all treatments are covered by public health insurance. In January 2025, Luxembourg updated its regulations to phase-out high-THC flower products, now permitting only balanced or high-CBD flower and oil-based extracts. This shift reflects the government's commitment to standardized, pharmaceutical-grade cannabis therapies and patient safety. Tilray Deutschland GmbH was awarded the official government tender in 2025 to supply medical cannabis flower, demonstrating our leadership in centralized procurement and compliance with Luxembourg's rigorous standards.

*Portugal*. Portugal legalized medical cannabis in July 2018. The regulatory framework is overseen by INFARMED, requiring Market Placement Authorization (ACM) for all non-pharmaceutical cannabis products, with strict GACP and GMP compliance. While domestic patient access remains limited due to stringent product approvals and the absence of public reimbursement, Portugal has emerged as a leading European producer and exporter of medical cannabis, supplying high-value markets such as Germany, Poland, and Australia. In 2021, Tilray received the first Authorization for Placement on the Market for dried flower, with additional product approvals in 2024, reinforcing our pioneering role in Portugal's medical cannabis sector. Our strategic investments in cultivation and manufacturing, combined with robust compliance and documentation standards, enable Tilray to deliver EU-GMP quality products to both domestic and international markets. As Portugal explores adult-use reform, Tilray's established reputation and operational excellence position us to capitalize on future regulatory developments and market expansion.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25

------

***Wellness market trends:***

Tilray Wellness's branded business continues to grow across brick-and-mortar retail as well as ecommerce, further establishing its leading market share position in better-for-you categories. The Company continues to focus on value-added innovation within natural and organic food and beverages across branded and ingredient sales. We continue to participate in multiple growing categories including super-seeds, better for you breakfast, better for you snacking, and natural energy drinks. Within our Ingredients sales business, we have expanded our range of offerings in hemp protein and hemp oil, helping us further develop our business in North America and Asia.

**Acquisitions, Strategic Transactions and Synergies**

We strive to continue to expand our business, on a consolidated basis, through a combination of organic growth and acquisition. While we continue to execute against our strategic initiatives that we believe will result in long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to enter attractive new geographic markets and product categories as well as expand our existing capabilities. In addition, we have exited certain businesses and continue to evaluate certain businesses within our portfolio that are dilutive to profitability and cash flow. As a result, we incur transaction costs in connection with identifying and completing acquisitions and strategic transactions, as well as ongoing integration and restructuring costs as we combine acquired companies and continue to achieve synergies, which is offset by income generated in connection with the execution of these transactions. For the six months ended November 30, 2025, we incurred $1.0 million of transaction expenses, as discussed further below.

***Beverage segment Project 420:***

In November 2020, we entered the beverage category with the acquisition of SweetWater Brewing Company, one of the largest independent craft brewers in the U.S. by volume, with the vision of creating a more diversified global lifestyle consumer products company.

This initial acquisition provided us with a foundation to pursue additional acquisitions in the beverage category and scale our business on a national basis. We acquired Alpine Beer Company, Green Flash and Breckenridge Distillery in December 2021, Montauk Brewing Company in November 2022, Craft Acquisition I in October 2023 and Craft Acquisition II in September 2024.

With Craft Acquisition I and Craft Acquisition II, we capitalized on opportunities to acquire additional beverage businesses that consisted of strong brands in decline due to lack of focus and in need of investment in order to promote growth, all at a significantly reduced purchase price. To support the growth of these acquired brands and establish a clear path to profitability, we implemented Project 420, which is a comprehensive plan covering (i) SKU optimization/rationalization; (ii) Geographic rationalization; (iii) Distributor rationalization; and (iv) synergy optimization plan through which we expect to invest in the acquired brands for growth and improve profitability:

- *<u>SKU optimization/rationalization</u>* – In response to the declining growth in the craft beer industry and consolidation of distributors, we are working with our distributors in various markets to streamline our portfolio by eliminating duplicative, lower margin and slower growth products, which has the immediate effect of reducing revenue. However, by eliminating these slower moving and lower margin SKUs, we are able to focus our attention and resources on our higher margin and faster growing SKUs, as well as the introduction of new innovation, which we expect will accelerate our revenue growth in future quarters.

*<u>Geographic rationalization</u>* – On a consolidated basis, we generate sales in all states however, our brands are significantly stronger in their home markets. For example, SweetWater is located in Georgia and, as a result, its revenues are stronger in Georgia, Alabama, North Carolina and Florida, while 10 Barrel, which is located in Oregon has stronger revenue in Oregon, Washington, Idaho and Wyoming. In away markets, like Oregon for SweetWater, and Georgia for 10 Barrel, the brands are not as strong in these "away" states. Our geographic rationalization works to concentrate our efforts in individual states with our strongest brands in those states. As we reduce the distribution of away markets brands in those states, we are working to increase the distribution and shelf space of home market brands. This initiative is consistent with our Regional Jewel strategy developed in conjunction with the Boston Consulting Group.<br>

*<u>Distributor rationalization</u>* – As a result of our various acquisitions in the last five years, we have over 750 distributors and 975 distributor shipping locations. As a result, we are shipping to multiple distributors in the same geography as well as splitting the allocation of local brands between multiple distributors. The goal of the distributor rationalization is to reduce our distributor footprint down to between 450 and 500 distributors, concentrating those distributors' effort on our brands and SKUs, while minimizing logistical complexities.

*<u>Synergy optimization plan</u>* – We previously announced a $33 million synergy plan focused on optimizing our production footprint and eliminating redundancies in manufacturing and warehouse assets. By integrating the newly acquired facilities into our existing footprint, we are optimizing capacities, utilization and better absorbing fixed overheads. This in turn is improving our gross margins. As of November 30, 2025, we have achieved $27.2 million of those savings to date. We expect to complete the synergy optimization plan in the fourth quarter of fiscal 2026.<br>

<u>*Brand and business investment*</u> – We have been and are continuing to increase our investment in the marketing, promotion and infrastructure of our recently acquired brands in order to re-establish their dominance in their core markets. Our intention is to fund this investment through the cost savings and synergies achieved through Project 420. <br>

It is important to note, however, that there is a lag between the discontinuation of the SKUs and the associated reduction in revenue, which has an immediate effect, and the acceleration of the growth of our existing SKUs and the introduction of new innovation and the associated increase in revenue, which takes time due to retailer resets. We also expect these efforts will lead to improved sales and margins, with benefits realized through lower selling costs, as well as reduced requirements for working capital through inventory reductions and an improvement in our cash conversion cycle.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26

------

**Political and Economic Environment**

Our results of operations may continue to be affected by economic, political, legislative, regulatory, legal actions, global volatility and general market disruption resulting from geopolitical tensions, such as Russia's continued incursion into Ukraine, the ongoing events in the Middle East and political uncertainty in certain countries in Europe. Economic conditions, such as recessionary trends, inflation, supply chain disruptions, interest and monetary exchange rates, government fiscal policies, and the recent economic uncertainties resulting from certain changes in U.S. global economic policy, including changes on global trade policies can have a significant effect on operations. More specifically, there are no expected impacts on revenue from the recently enacted U.S. tariffs and foreign enacted retaliatory tariffs ("Tariffs"). From a cost perspective, we believe the recently enacted Tariffs could impact input materials such as aluminum, hops, barley, malt and vape componentry, which are partially imported but we intend to mitigate these impacts to the extent possible.

In addition, U.S. federal regulatory developments regarding cannabis rescheduling represent a significant shift in the political and legislative environment. This regulatory evolution is expected to create a more credible framework for medical cannabis research, clinical development, and compliance, aligning with Tilray's established global expertise in regulated medical cannabis markets; although, there are no assurances whether such rescheduling will be implemented as and when anticipated. The Company intends to leverage its proven compliance infrastructure, scientific knowledge, and operational scale to expand responsibly in the U.S. market, introducing medical-grade cannabis products in targeted therapeutic formats. While these developments present significant long-term growth opportunities, they also introduce new regulatory complexities and potential risks that we will continue to monitor closely.

**Reverse Stock Split**

Effective December 2, 2025, we implemented a Reverse Stock Split of our outstanding shares of Common Stock, at a ratio of one-for-ten.

All issued and outstanding Common Stock, per share amounts, and outstanding equity instruments and awards exercisable into Common Stock contained in the condensed interim consolidated financial statements of the Company and notes thereto have been retroactively adjusted to reflect the Reverse Stock Split for all current and prior periods presented.

**Results of Operations**

Our consolidated results, in thousands except for per share data, are as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Net revenue | $217507 | $210950 | $6557 | 3% | $427008 | $410994 | $16014 | 4% |
| Cost of goods sold | 160010 | 149730 | 10280 | 7% | 312042 | 290068 | 21974 | 8% |
| Gross profit | 57497 | 61220 | (3723) | (6)% | 114966 | 120926 | (5960) | (5)% |
| Operating expenses: |  |  |  |  |  |  |  |  |
| General and administrative | 51175 | 45997 | 5178 | 11% | 92228 | 90110 | 2118 | 2% |
| Selling | 11781 | 16162 | (4381) | (27)% | 24704 | 27852 | (3148) | (11)% |
| Amortization | 4358 | 22927 | (18569) | (81)% | 8287 | 44731 | (36444) | (81)% |
| Marketing and promotion | 9981 | 9720 | 261 | 3% | 20136 | 21286 | (1150) | (5)% |
| Research and development | 78 | 60 | 18 | 30% | 119 | 165 | (46) | (28)% |
| Change in fair value of contingent consideration |  |  |  | NM | (15000) |  | (15000) | NM |
| Litigation costs, net of recoveries | 869 | 901 | (32) | (4)% | 1876 | 2496 | (620) | (25)% |
| Restructuring costs | 965 | 6869 | (5904) | (86)% | 1834 | 11116 | (9282) | (84)% |
| Transaction costs (income), net | 569 | 802 | (233) | (29)% | 969 | 1958 | (989) | (51)% |
| Total operating expenses | 79776 | 103438 | (23662) | (23)% | 135153 | 199714 | (64561) | (32)% |
| Operating loss | (22279) | (42218) | 19939 | (47)% | (20187) | (78788) | 58601 | (74)% |
| Interest expense, net | (5374) | (7766) | 2392 | (31)% | (12070) | (17608) | 5538 | (31)% |
| Non-operating (expense) income, net | (12310) | (33255) | 20945 | (63)% | (8478) | (20609) | 12131 | (59)% |
| Loss before income taxes | (39963) | (83239) | 43276 | (52)% | (40735) | (117005) | 76270 | (65)% |
| Income tax expense (recovery), net | 3546 | 2036 | 1510 | 74% | 1261 | 2922 | (1661) | (57)% |
| Net loss | $(43509) | $(85275) | $41766 | (49)% | $(41996) | $(119927) | $77931 | (65)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27

------

**Use of Non-GAAP Measures**

Throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q, we discuss non-GAAP financial measures, including references to:

● adjusted gross profit (excluding purchase price allocation ("PPA") step up) consolidated and for each reporting segment (Cannabis, Beverage, Distribution and Wellness),

● adjusted gross margin (excluding PPA step up) consolidated and for each reporting segment (Cannabis, Beverage, Distribution and Wellness),

● adjusted EBITDA, 

● cash and marketable securities, and

● constant currency presentation of net revenue (by segment and consolidated).

These non-GAAP financial measures should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with generally accepted accounting principles in the United States of America, ("GAAP"). These financial measures, which may be different than similarly titled financial measures used by other companies, are presented to help investors' overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Please see "Reconciliation of Non-GAAP Financial Measures to GAAP Measures" below for reconciliation of such non-GAAP financial measures to the most directly comparable GAAP financial measures, as well as a discussion of our adjusted gross margin, adjusted gross profit and adjusted EBITDA measures and the calculation of such measures.

*Constant Currency Presentation*

We believe that this financial measure provides useful information to investors because it eliminates the effect that foreign currency exchange rate fluctuations may have on period-to-period comparability given the volatility in foreign currency exchange markets and therefore, provides greater transparency to the underlying performance of our consolidated net sales. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. Dollar are translated into U.S. Dollars at the average monthly exchange rate in effect during the corresponding period of the prior fiscal year rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

*Cash and Marketable Securities*

The Company combines the Cash and cash equivalent financial statement line item and the Marketable securities financial statement line item as an aggregate total as reconciled in the liquidity and capital resource section below. The Company's management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combining these two GAAP metrics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 28

------

**Operating Metrics and Non-GAAP Measures**

We use the operating metrics and non-GAAP measures set forth in the table below to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. Other companies, including companies in our industry, may calculate operating metrics and non-GAAP measures with similar names differently which may reduce their usefulness as comparative measures. Certain variances are labeled as not meaningful ("NM") throughout management's discussion and analysis.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** | **For the six months ended** | **For the six months ended** |
|  | **November 30,** | **November 30,** | **November 30,** | **November 30,** |
| **(in thousands of U.S. dollars)** | **2025** | **2024** | **2025** | **2024** |
| Net beverage revenue | $50083 | $63081 | $105822 | $119053 |
| Net cannabis revenue | 67532 | 65652 | 132043 | 126901 |
| Distribution revenue | 85316 | 67611 | 159323 | 135682 |
| Wellness revenue | 14576 | 14606 | 29820 | 29358 |
| Beverage costs | 34351 | 37925 | 68764 | 70975 |
| Cannabis costs | 41398 | 42475 | 82639 | 79529 |
| Distribution costs | 74334 | 59207 | 140342 | 119345 |
| Wellness costs | 9927 | 10123 | 20297 | 20219 |
| Adjusted gross profit (excluding PPA step-up) (1) | 57497 | 62596 | 114966 | 122477 |
| Beverage adjusted gross margin (excluding PPA step-up) (1) | 31% | 42% | 35% | 42% |
| Cannabis adjusted gross margin (excluding PPA step-up) (1) | 39% | 35% | 37% | 37% |
| Distribution gross margin | 13% | 12% | 12% | 12% |
| Wellness gross margin | 32% | 31% | 32% | 31% |
| Adjusted EBITDA (1) | $8365 | $9017 | $18546 | $18351 |
| Cash and marketable securities (1) as at the period ended: | 291551 | 252249 | 291551 | 252249 |
| Working capital as at the period ended: | $470002 | $428815 | $470002 | $428815 |

---

*<sup>(1)</sup> Adjusted EBITDA, adjusted gross profit (excluding PPA step-up) and adjusted gross margin (excluding PPA step-up) for each of our segments, and cash and marketable securities are non-GAAP financial measures. See "Use of Non-GAAP Measures" above for a discussion of these Non-GAAP measures and "Reconciliation of Non-GAAP Financial Measures to GAAP Measures" below for a reconciliation of these Non-GAAP Measures to our most comparable GAAP measure and the discussion above captioned "Cash and Marketable Securities."*

**Segment Reporting**

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, our reporting segments net revenue was comprised of net revenues from our beverage, cannabis, distribution, and wellness operations as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Beverage business | $50083 | $63081 | $(12998) | (21)% | $105822 | $119053 | $(13231) | (11)% |
| Cannabis business | 67532 | 65652 | 1880 | 3% | 132043 | 126901 | 5142 | 4% |
| Distribution business | 85316 | 67611 | 17705 | 26% | 159323 | 135682 | 23641 | 17% |
| Wellness business | 14576 | 14606 | (30) | (0)% | 29820 | 29358 | 462 | 2% |
| Total net revenue | $217507 | $210950 | $6557 | 3% | $427008 | $410994 | $16014 | 4% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 29

------

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, our reporting segment net revenue on a constant currency<sup>(1)</sup> basis was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **as reported in constant currency** | **as reported in constant currency** |  |  | **as reported in constant currency** | **as reported in constant currency** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Beverage business | $50083 | $63081 | $(12998) | (21)% | $105822 | $119053 | $(13231) | (11)% |
| Cannabis business | 67486 | 65652 | 1834 | 3% | 131535 | 126901 | 4634 | 4% |
| Distribution business | 79961 | 67611 | 12350 | 18% | 149667 | 135682 | 13985 | 10% |
| Wellness business | 14734 | 14606 | 128 | 1% | 30015 | 29358 | 657 | 2% |
| Total net revenue | $212264 | $210950 | $1314 | 1% | $417039 | $410994 | $6045 | 1% |

---

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, our geographic net revenue was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| USA | $57838 | $71753 | $(13915) | (19)% | $121799 | $135633 | $(13834) | (10)% |
| Canada | 54173 | 56720 | (2547) | (4)% | 112340 | 112625 | (285) | (0)% |
| EMEA | 103155 | 79254 | 23901 | 30% | 188408 | 156926 | 31482 | 20% |
| Rest of World | 2341 | 3223 | (882) | (27)% | 4461 | 5810 | (1349) | (23)% |
| Total net revenue | $217507 | $210950 | $6557 | 3% | $427008 | $410994 | $16014 | 4% |

---

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, our geographic net revenue on a constant currency<sup>(1)</sup> basis was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **as reported in constant currency** | **as reported in constant currency** |  |  | **as reported in constant currency** | **as reported in constant currency** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| USA | $57838 | $71753 | (13915) | (19)% | $121799 | $135633 | (13834) | (10)% |
| Canada | 55413 | 56720 | (1307) | (2)% | 113849 | 112625 | 1224 | 1% |
| EMEA | 96391 | 79254 | 17137 | 22% | 176399 | 156926 | 19473 | 12% |
| Rest of World | 2622 | 3223 | (601) | (19)% | 4992 | 5810 | (818) | (14)% |
| Total net revenue | $212264 | $210950 | $1314 | 1% | $417039 | $410994 | $6045 | 1% |

---

As of November 30, 2025 and May 31, 2025, respectively, our geographic capital assets were as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **November 30,** | **May 31,** | **Change** | **% Change** |
| **(in thousands of U.S. dollars)** | **2025** | **2025** | **2025 vs. 2024** | **2025 vs. 2024** |
| USA | $193897 | $200003 | $(6106) | (3)% |
| Canada | 253515 | 267458 | (13943) | (5)% |
| EMEA | 98446 | 97371 | 1075 | 1% |
| Rest of World | 4243 | 3601 | 642 | 18% |
| Total capital assets | $550101 | $568433 | $(18332) | (3)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 30

------

**Beverage revenue** 

Net revenue from our Beverage segment decreased to $50.1 million and to $105.8 million for the three and six months ended November 30, 2025, compared to revenue of $63.1 million and $119.1 million for the prior year periods. The decline in revenue was primarily driven by continued category challenges within the craft beer segment and competitive pressures. Additionally, our portfolio optimization efforts under Project 420, which include SKU rationalization and margin-focused initiatives, contributed to the year-over-year decrease.

For the six month period ended November 30, 2025, these impacts were partially offset by the inclusion of sales from Craft Acquisition II, effective September 1, 2024, which were not reflected in the full prior-year comparative period.

**Cannabis revenue** 

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, cannabis net revenue based on market channel was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Revenue from Canadian medical cannabis | $6234 | $6673 | $(439) | (7)% | $12380 | $12934 | $(554) | (4)% |
| Revenue from Canadian adult-use cannabis | 62448 | 59077 | 3371 | 6% | 126515 | 116312 | 10203 | 9% |
| Revenue from wholesale cannabis | 1346 | 6593 | (5247) | (80)% | 5501 | 12100 | (6599) | (55)% |
| Revenue from international cannabis | 20180 | 14865 | 5315 | 36% | 33547 | 27056 | 6491 | 24% |
| Total cannabis revenue | 90208 | 87208 | 3000 | 3% | 177943 | 168402 | 9541 | 6% |
| Excise taxes | (22676) | (21556) | (1120) | 5% | (45900) | (41501) | (4399) | 11% |
| Total cannabis net revenue | $67532 | $65652 | $1880 | 3% | $132043 | $126901 | $5142 | 4% |

---

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, cannabis net revenue based on market channel on a constant currency<sup>(1)</sup> basis was as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **as reported in constant currency** | **as reported in constant currency** |  |  | **as reported in constant currency** | **as reported in constant currency** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Revenue from Canadian medical cannabis | $6380 | $6673 | $(293) | (4)% | $12554 | $12934 | $(380) | (3)% |
| Revenue from Canadian adult-use cannabis | 63877 | 59077 | 4800 | 8% | 128236 | 116312 | 11924 | 10% |
| Revenue from wholesale cannabis | 1373 | 6593 | (5220) | (79)% | 5546 | 12100 | (6554) | (54)% |
| Revenue from international cannabis | 19053 | 14865 | 4188 | 28% | 31727 | 27056 | 4671 | 17% |
| Total cannabis revenue | 90683 | 87208 | 3475 | 4% | 178063 | 168402 | 9661 | 6% |
| Excise taxes | (23197) | (21556) | (1641) | 8% | (46528) | (41501) | (5027) | 12% |
| Total cannabis net revenue | $67486 | $65652 | $1834 | 3% | $131535 | $126901 | $4634 | 4% |

---

 *(1)* *The constant currency presentation of our Cannabis revenue based on market channel is a non-GAAP financial measure. See* "*Use of Non-GAAP Measures* –*Constant Currency Presentation*" *above for a discussion of these Non-GAAP Measures.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 31

------

***Revenue from Canadian medical cannabis:*** Gross revenue from Canadian medical cannabis decreased to $6.2 million and to $12.4 million for the three and six months ended November 30, 2025 compared to gross revenue of $6.7 million and $12.9 million for the prior year periods, respectively. On a constant currency basis, gross revenue from Canadian medical cannabis decreased to $6.4 million and to $12.6 million for the three and six months ended November 30, 2025, respectively. The decrease in gross revenue from medical cannabis, on a constant currency basis, was primarily driven by uninsured patient attrition to the adult-use recreational market, which was partially offset by new insured patient acquisition.

***Revenue from Canadian adult-use cannabis:*** During the three and six months ended November 30, 2025, our gross revenue from Canadian adult-use cannabis increased to $62.4 million and to $126.5 million, compared to gross revenue of $59.1 million and $116.3 million for the prior year periods, respectively. On a constant currency basis, our gross revenue from Canadian adult-use cannabis increased to $63.9 million and increased to $128.2 million for the three and six months ended November 30, 2025, respectively. The increase in gross adult-use revenue was primarily attributed to sales growth in our flower and non-infused pre-roll categories where we have begun to see positive results from our continued innovation and enhanced cultivation capacity. Additionally, we have started to re-enter price-compressed categories that were previously margin prohibitive but are now generating positive gross margins due to our ongoing cost savings initiatives. Lastly, we have continued to invest in our cultivation footprint, including the decision to restart cultivation in our Quebec facility, to support the growing demand in both the Canadian and international markets. Given the higher margin that can be earned on international cannabis sales, we may, when advantageous to do so, continue to redirect inventories to international markets, which may negatively impact Canadian adult-use and wholesale cannabis revenue in future periods while we scale up our infrastructure.

***Wholesale cannabis revenue:*** Gross revenue from wholesale cannabis decreased to $1.3 million and to $5.5 million and for the three and six months ended November 30, 2025, compared to gross revenue of $6.6 million and $12.1 million for the prior year periods respectively. On a constant currency basis, gross revenue from wholesale cannabis decreased to $1.4 million and decreased to $5.5 million for the three and six months ended November 30, 2025, respectively. Due to the transition by many licensed producers in the Canadian market to asset-light business models, the Canadian cannabis industry has experienced a reduction in excess inventory resulting in price increases in the B2B market. As a result of this shift in market dynamics and demand, we continue to evaluate the market and may opportunistically sell into the wholesale market where it makes sense. Specifically, during the three and six month periods ended November 30, 2025, our wholesale cannabis revenue was lower than the prior year comparative periods due to our strategic decision to channel more of our volume into the other markets in which we participate.

***International cannabis revenue:*** Net revenue from International cannabis increased to $20.2 million and to $33.5 million for the three and six months ended November 30, 2025, compared to net revenue of $14.9 million and $27.1 million for the prior year periods, respectively. On a constant currency basis, given the strengthening of the Euro against the U.S. Dollar when compared to the prior year quarter, net revenue from international cannabis increased to $19.1 million and to $31.7 million for the three and six months ended November 30, 2025, respectively. The increase in net revenue from International cannabis markets during the three and six months ended November 30, 2025, was attributed to growth in the German medical cannabis market, receipt of previously backlogged permits and expansion into emerging medical markets. International cannabis net revenue may fluctuate from quarter to quarter based upon the timing of the receipt of export/import permits as well as the timing of shipments from one quarter to the next. Notably, International cannabis revenue in the first fiscal quarter ended August 31, 2025, was temporarily reduced due to permit-related delays. As these delays were resolved, revenue levels in the second fiscal quarter ended November 30, 2025, which were consistent with those achieved in the fourth fiscal quarter ended May 31, 2025, of the prior fiscal year, are more indicative of our expected ongoing run rate than the lower revenue realized in the first quarter.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 32

------

**Distribution revenue** 

Net revenue from our Distribution segment increased to $85.3 million and increased to $159.3 million for the three and six months ended November 30, 2025, compared to revenue of $67.6 million and $135.7 million for the prior year periods, respectively. On a constant currency basis, given the change in the Euro and Argentine Peso against the U.S. Dollar in the quarter, revenue from Distribution increased to $80.0 million and to $149.7 million for the three and six months ended November 30, 2025, respectively. The increase in distribution revenue in the period was driven by a focus on competitive pricing, prioritizing high velocity SKUs and the favorable impacts of foreign exchange.

**Wellness revenue** 

Our Wellness segment net revenue remained consistent at $14.6 million and increased to $29.8 million for the three and six months ended November 30, 2025 compared to $14.6 million and $29.4 million from the prior year periods, respectively. On a constant currency basis for the three and six months ended November 30, 2025, Wellness segment net revenue increased to $14.7 million and to $30.0 million, respectively. The increase in revenue was driven by our strategic focus on value-add innovations, including high protein super-seeds, better-for-you breakfast products, better-for-you snacking, and the continued success of our Hi-Ball clean energy drinks. Additionally, there was continued growth experienced in the ingredient channel as a result of new customer acquisitions. These trends were partially offset by challenges in the club retailer channel, which we are actively addressing through targeted initiatives.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 33

------

**Gross profit, gross margin and adjusted gross margin<sup>(1)</sup> for our reporting segments**

For the three and six months ended November 30, 2025 and November 30, 2024, respectively, our gross profit and gross margin were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
| **(in thousands of U.S. dollars)** | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **Beverage** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Net revenue | $50083 | $63081 | $(12998) | (21)% | $105822 | $119053 | $(13231) | (11)% |
| Cost of goods sold | 34351 | 37925 | (3574) | (9)% | 68764 | 70975 | (2211) | (3)% |
| Gross profit | 15732 | 25156 | (9424) | (37)% | 37058 | 48078 | (11020) | (23)% |
| Gross margin | 31% | 40% | (9)% | (23)% | 35% | 40% | (5)% | (13)% |
| Purchase price accounting step-up |  | 1376 | (1376) | (100)% |  | 1551 | (1551) | (100)% |
| Adjusted gross profit (1) | 15732 | 26532 | (10800) | (41)% | 37058 | 49629 | (12571) | (25)% |
| Adjusted gross margin (1) | 31% | 42% | (11)% | (26)% | 35% | 42% | (7%) | (17%) |
| **Cannabis** |  |  |  |  |  |  |  |  |
| Net revenue | 67532 | 65652 | 1880 | 3% | 132043 | 126901 | 5142 | 4% |
| Cost of goods sold | 41398 | 42475 | (1077) | (3)% | 82639 | 79529 | 3110 | 4% |
| Gross profit | 26134 | 23177 | 2957 | 13% | 49404 | 47372 | 2032 | 4% |
| Gross margin | 39% | 35% | 4% | 11% | 37% | 37% | 0% | 0% |
| **Distribution** |  |  |  |  |  |  |  |  |
| Net revenue | 85316 | 67611 | 17705 | 26% | 159323 | 135682 | 23641 | 17% |
| Cost of goods sold | 74334 | 59207 | 15127 | 26% | 140342 | 119345 | 20997 | 18% |
| Gross profit | 10982 | 8404 | 2578 | 31% | 18981 | 16337 | 2644 | 16% |
| Gross margin | 13% | 12% | 1% | 8% | 12% | 12% | 0% | 0% |
| **Wellness** |  |  |  |  |  |  |  |  |
| Net revenue | 14576 | 14606 | (30) | (0)% | 29820 | 29358 | 462 | 2% |
| Cost of goods sold | 9927 | 10123 | (196) | (2)% | 20297 | 20219 | 78 | 0% |
| Gross profit | 4649 | 4483 | 166 | 4% | 9523 | 9139 | 384 | 4% |
| Gross margin | 32% | 31% | 1% | 3% | 32% | 31% | 1% | 3% |
| **Total** |  |  |  |  |  |  |  |  |
| Net revenue | 217507 | 210950 | 6557 | 3% | 427008 | 410994 | 16014 | 4% |
| Cost of goods sold | 160010 | 149730 | 10280 | 7% | 312042 | 290068 | 21974 | 8% |
| Gross profit | 57497 | 61220 | (3723) | (6)% | 114966 | 120926 | (5960) | (5)% |
| Gross margin | 26% | 29% | (3)% | (10)% | 27% | 29% | (2)% | (7)% |
| Purchase price accounting step-up |  | 1376 | (1376) | (100)% |  | 1551 | (1551) | (100)% |
| Adjusted gross profit (1) | 57497 | 62596 | (5099) | (8)% | 114966 | 122477 | (7511) | (6)% |
| Adjusted gross margin (1) | 26% | 30% | (4)% | (13)% | 27% | 30% | (3)% | (10)% |

---

*(1)* *Adjusted gross profit is our Gross profit (adjusted to exclude purchase price accounting valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude purchase price accounting valuation step-up) for each segment are non-GAAP financial measures. See* "*Use of Non-GAAP Measures*" *above for additional discussion regarding these non-GAAP measures. The Company*'*s management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin in isolation or as an alternative to financial measures determined in accordance with GAAP.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 34

------

*Beverage gross margin:* For the three and six months ended November 30, 2025, our beverage segment generated gross margin of 31% and 35%, respectively, which decreased from 40% and 40% generated in the prior year periods, respectively. Adjusted gross margin was 31% and 35%, which decreased from 42% and 42% generated in the prior year periods, respectively. The change in the beverage gross margin and adjusted beverage gross margin for the three and six months ended November 30, 2025 was driven by several factors, including our Craft Acquisition II, which historically has operated at a lower gross margin, declining overhead utilization as our revenue levels have declined, and timing delays in realizing the full benefits of our Project 420 cost savings initiatives.

*Cannabis gross margin:* For the three and six months ended November 30, 2025, our cannabis segment generated gross margin of 39% and 37%, respectively, which increased from 35% and remained consistent at 37% generated in the prior year periods, respectively. The change in gross margin for the three and six months ended November 30, 2025 was driven by a higher proportion of our sales being generated from international markets which has higher margins and lower participation in Canadian wholesale markets which generates lower margins. These favorable impacts were offset by our increased participation in lower margin product categories in the Canadian adult-use cannabis market, as we continue to optimize our cost structure to eliminate negative margins in price competitive categories.

*Distribution gross margin:* For the three and six months ended November 30, 2025, our distribution segment generated gross margin of 13% and 12%, respectively, which increased from 12% and remained consistent at 12% generated in the prior year periods, respectively, which was attributed to a change in product mix combined with foreign exchange rate improvements, as well as initiatives undertaken to reduce input costs.

*Wellness gross margin:* For the three and six months ended November 30, 2025, our wellness segment generated gross margin of 32% and 32%, respectively, which increased from 31% and 31% in the prior year periods, respectively, as a result of a change in product mix.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35

------

**Operating expenses**

During the three and six months ended November 30, 2025 and November 30, 2024, respectively, the changes in operating expenses were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| General and administrative | $51175 | $45997 | $5178 | 11% | $92228 | $90110 | $2118 | 2% |
| Selling | 11781 | 16162 | (4381) | (27)% | 24704 | 27852 | (3148) | (11)% |
| Amortization | 4358 | 22927 | (18569) | (81)% | 8287 | 44731 | (36444) | (81)% |
| Marketing and promotion | 9981 | 9720 | 261 | 3% | 20136 | 21286 | (1150) | (5)% |
| Research and development | 78 | 60 | 18 | 30% | 119 | 165 | (46) | (28)% |
| Change in fair value of contingent consideration |  |  |  | NM | (15000) |  | (15000) | NM |
| Litigation costs, net of recoveries | 869 | 901 | (32) | (4)% | 1876 | 2496 | (620) | (25)% |
| Restructuring costs | 965 | 6869 | (5904) | (86)% | 1834 | 11116 | (9282) | (84)% |
| Transaction costs (income), net | 569 | 802 | (233) | (29)% | 969 | 1958 | (989) | (51)% |
| Total operating expenses | $79776 | $103438 | $(23662) | (23)% | $135153 | $199714 | $(64561) | (32)% |

---

Operating expenses are comprised of general and administrative, selling, amortization, marketing and promotion, research and development, change in fair value of contingent consideration, litigation costs, net of recoveries, restructuring costs and transaction costs (income), net. For the three and six months ended November 30, 2025, operating expenses decreased by $23.7 million and by $64.6 million to $79.8 million and $135.2 million when compared to $103.4 million and $199.7 for the prior year periods, respectively. This decrease was primarily attributed to the lower amortization expense in the current period, which resulted from the intangible asset reduction recorded during the fiscal quarter ended May 31, 2025, as well as, a gain from the change in fair value of the Montauk contingent consideration, and, to a lesser extent, a reduction in non-recurring litigation, restructuring and transaction costs, as well as selling costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36

------

**General and administrative costs**

During the three and six months ended November 30, 2025 and November 30, 2024, respectively, the changes in general and administrative costs when compared to the prior year period were as follows:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Salaries and wages | $24764 | $22726 | $2038 | 9% | $46500 | $44293 | $2207 | 5% |
| Office and general | 8284 | 9458 | (1174) | (12)% | 16981 | 18718 | (1737) | (9)% |
| Stock-based compensation | 12283 | 7237 | 5046 | 70% | 17335 | 14154 | 3181 | 22% |
| Insurance | 2456 | 3155 | (699) | (22)% | 4849 | 5610 | (761) | (14)% |
| Professional fees | 1034 | 1126 | (92) | (8)% | 2252 | 2304 | (52) | (2)% |
| Gain on sale of capital assets | (134) | (505) | 371 | (73)% | (375) | (531) | 156 | (29)% |
| Travel and accommodation | 1292 | 1754 | (462) | (26)% | 2604 | 3247 | (643) | (20)% |
| Rent | 1196 | 1046 | 150 | 14% | 2082 | 2315 | (233) | (10)% |
| Total general and administrative costs | $51175 | $45997 | $5178 | 11% | $92228 | $90110 | $2118 | 2% |

---

Salaries and wages increased by 9% and by 5% during the three and six months ended November 30, 2025 when compared to the prior year periods, respectively. The increase during the three and six months ended November 30, 2025 was primarily due to the inclusion of employees from our Craft Acquisition II, which was effective as of September 1, 2024 and therefore, its salaries and wages were not included in the prior year first quarter and as a result of changes in estimates related to timing of compensation accruals. In addition, included in the six month period ended November 30, 2025, was $1.8 million of retention payments compared to $1.7 million in the prior year six month period ended November 30, 2024.

Office and general decreased by 12% and by 9% during the three and six months ended November 30, 2025 when compared to the prior year period respectively. The decrease was driven by our ongoing cost saving initiatives despite the inclusion of costs from our Craft Acquisition II, which was effective as of September 1, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 37

------

The Company recognized stock-based compensation expense of $12.3 million and $17.3 million for the three and six months ended November 30, 2025 compared to $7.2 million and $14.2 million for the prior year period respectively. Stock-based compensation expense is based on the time-based vesting schedules and varies according to the assumptions used in the vesting model. During the three and six months ended November 30, 2025, stock-based compensation increased as a result of the recognition of expenses related to the performance-based grants following the establishment of their performance criteria during the fiscal quarter.

Insurance expense decreased by 22% and decreased by 14% for the three and six months ended November 30, 2025 to $2.5 million and $4.8 million from $3.2 million and $5.6 million for the prior year period respectively due to lower premiums as a result of management's decision to self-insure a portion of our property and casualty insurance.

Rent expense increased by 14% and decreased by 10% for the three and six months ended November 30, 2025 to $1.2 million and $2.1 million compared to $1.0 million and $2.3 million for the prior year periods, respectively. Rent expense is predominantly comprised of operating lease expenses for our brew pubs and office spaces and varies period-over-period based on lease amortization schedules and common area maintenance costs.

**Selling costs**

For the three and six months ended November 30, 2025, the Company incurred selling costs of $11.8 million or 5% of net revenue and $24.7 million or 6% of net revenue as compared to $16.2 million or 8% of net revenue and $27.9 million or 7% of net revenue in the prior year period respectively. These costs relate to third-party shipping costs for all segments, in addition to distributor commission incurred by the cannabis segment, Health Canada cannabis fees, and patient acquisition and maintenance costs. The decrease in selling costs for the three and six months ended November 30, 2025 is from the lower freight costs incurred in the beverage segment as a result of Project 420 cost saving initiatives and lower commission rates experienced in the Canadian cannabis sales channels.

**Amortization**

The Company incurred non-production related amortization charges of $4.4 million and $8.3 million for the three and six months ended November 30, 2025, compared to $22.9 million and $44.7 million in the prior year periods respectively based on depreciable capital and intangible assets useful lives. The decrease in the amortization expense is due to the lower carrying value of intangible assets as a result of the impairment charges recognized during the fiscal year ended May 31, 2025.

**Marketing and promotion costs** 

For the three and six months ended November 30, 2025, the Company incurred marketing and promotion costs of $10.0 million and $20.1 million compared to $9.7 million and $21.3 million for the prior year periods, respectively and was driven by variability in discretionary marketing spend.

**Research and development**

Research and development costs were $0.1 million and $0.1 million during the three and six months ended November 30, 2025, compared to $0.1 million and $0.2 million in the prior year periods, respectively. These cost relate to external expenditures associated with the development of new products.

**Change in fair value of contingent consideration**

The Company measures contingent consideration at fair value classified as Level 3, as discussed in Note 24 (Financial risk management and financial instruments). During the six months ended November 30, 2025, the Company recognized $15.0 million of change in the fair value of contingent consideration as the likelihood of achievement decreased to 0% of such contingent consideration related to the Montauk Brewing acquisition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 38

------

**Litigation costs, net of recoveries** 

For the three and six months ended November 30, 2025, the Company recorded $0.9 million and $1.9 million of litigation settlements costs and third-party fees incurred in defending these claims, net of favorable recoveries compared to $0.9 million and $2.5 million in the prior year period respectively. The increase is related to period-to-period variability as litigation and settlement costs are non-recurring in nature.

**Restructuring costs** 

In connection with the integration of certain acquisitions and strategic transactions, the Company has incurred restructuring and exit costs in the amount of $1.0 million and $1.8 million for the three and six months ended November 30, 2025, compared to $6.9 million and $11.1 million for the prior year period respectively. All restructuring plans are approved at the executive level, and their associated expenses are recognized in the period in which the plan is committed or otherwise incurred.

Within the Cannabis segment, during the six months ended November 30, 2025, the Company incurred restructuring-related expenses totaling $1.8 million. These charges included $0.7 million associated with the restructuring of the Quebec facility to transition from vegetable cultivation to cannabis cultivation in response to increased global cannabis demand, $0.8 million related to employee termination severance and benefits associated with the reorganization of the Canadian cannabis commercial function, and $0.2 million related to the wind-down of certain non-operating entities. Additionally, the Company recognized $0.1 million related to its Fort Collins, CO partially vacant warehouse recorded under assets held of sale. See Note 3 (capital assets).

During the fiscal year ended May 31, 2025, the Company accrued $8.5 million of restructuring charges related to the closure of Hop Valley and other Project 420 initiatives within the Beverage segment, of which $4.6 million was recognized in the six months ended November 30, 2025 thereby, reducing the accrual to $3.9 million.

**Transaction (income) costs, net**

Transaction (income) costs, net, include non-recurring acquisition related income and expenses, related legal, financial advisor and due diligence cost and expenses and transaction related compensation. For the three and six months ended November 30, 2025, transaction (income) costs, decreased by 29% to $0.6 million and $1.0 million, and decreased by 51% to $0.8 million and $2.0 million from the three and six months ended November 30, 2024, respectively. This decrease was due to the fact that we incurred higher costs in the prior year period in connection with Craft Acquisition II.

**Non-operating (expense) income, net**

During the three and six months ended November 30, 2025 and November 30, 2024, respectively, the changes in non-operating (expense), income were comprised of:

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **(in thousands of US dollars)** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Change in fair value of warrant liability | 175 | 862 | (687) | (80)% | (3495) | 1558 | (5053) | (324)% |
| Foreign exchange gain (loss) | (10327) | (33797) | 23470 | (69)% | (3399) | (21916) | 18517 | (84)% |
| Loss on long-term investments | (345) | (27) | (318) | 1178% | (306) | (66) | (240) | 364% |
| Unrealized loss on digital assets | (164) |  | (164) | NM | (172) |  | (172) | NM |
| Other non-operating (losses) gains, net | (1649) | (293) | (1356) | 463% | (1106) | (185) | (921) | 498% |
| Total non-operating income (expense) | $(12310) | $(33255) | $20945 | (63)% | $(8478) | $(20609) | $12131 | (59)% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39

------

For the three and six months ended November 30, 2025, the Company recognized a gain on the change in fair value of its warrants of $0.2 million and a loss of $3.5 million, compared to a gain of $0.9 million and $1.6 million in the prior year periods, as a result of the change in our share price and the exercise price of the warrants. For the three and six months ended November 30, 2025, the Company recognized a loss of $10.3 million and $3.4 million resulting from the changes in foreign exchange rates during the period compared to a loss of $33.8 million and $21.9 million for the prior year periods. For the three and six months ended November 30, 2025, the Company recognized a loss of $0.3 million and $0.3 million on long-term investments compared to a loss of $0.0 million and $0.1 million for the prior year periods. For the three and six months ended November 30, 2025, the Company recognized a loss of $0.2 million and $0.2 million on digital assets from the unrealized change in fair value of Bitcoin compared to $nil and $nil million for the prior year periods. The other non-operating (losses) gains, net were loss of $1.6 million and $1.1 million for the three and six months ended November 30, 2025, compared to a loss of $0.3 million and $0.2 million for the prior year periods, and was mainly comprised of a loss of $1.8 million on the change in fair value of assets held for sale related to Fort Collins, CO partially vacant warehouse, as described in Note 3 (capital assets), offset by a gain of $0.5 million resulting from the exchange transaction of the TLRY 27 Note, as described in Note 12 (Convertible debentures payable).

**Reconciliation of Non-GAAP Financial Measures to GAAP Measures**

**Adjusted EBITDA**

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as net loss/net income before income taxes, net interest expense, depreciation and amortization, purchase price accounting step-up on inventory, stock-based compensation, impairments, other than temporary change in fair value of convertible notes receivable, restructuring costs, transaction (income) costs net, litigation costs net of recoveries, change in fair value of contingent consideration, project 420 cost savings initiatives, unrealized currency gains and losses and other adjustments.

We believe that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to the Company's results of operations and financial condition. In addition, management uses this measure for reviewing the financial results of the Company and as a component of performance-based executive compensation.

We do not consider adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of adjusted EBITDA is that it excludes certain expenses and income that are required by U.S. GAAP to be recorded in our consolidated financial statements. In addition, adjusted EBITDA is subject to inherent limitations as this metric reflects the exercise of judgment by management about which expenses and income are excluded or included in determining adjusted EBITDA. In order to compensate for these limitations, management presents adjusted EBITDA in connection with GAAP results.

For three and six months ended November 30, 2025, adjusted EBITDA decreased to $8.4 million and increased to $18.5 million compared to $9.0 million and $18.4 million for the prior year periods and remained relatively consistent as we continue to execute on our strategic plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 40

------

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** |  |  | **For the six months ended** | **For the six months ended** |  |  |
|  | **November 30,** | **November 30,** | **Change** | **% Change** | **November 30,** | **November 30,** | **Change** | **% Change** |
| **Adjusted EBITDA reconciliation:** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** | **2025** | **2024** | **2025 vs. 2024** | **2025 vs. 2024** |
| Net loss | $(43509) | $(85275) | $41766 | (49)% | $(41996) | $(119927) | $77931 | (65)% |
| Income tax expense (recovery), net | 3546 | 2036 | 1510 | 74% | 1261 | 2922 | (1661) | (57)% |
| Interest expense, net | 5374 | 7766 | (2392) | (31)% | 12070 | 17608 | (5538) | (31)% |
| Non-operating income (expense), net | 12310 | 33255 | (20945) | (63)% | 8478 | 20609 | (12131) | (59)% |
| Amortization | 15958 | 34050 | (18092) | (53)% | 31519 | 65864 | (34345) | (52)% |
| Stock-based compensation | 12283 | 7237 | 5046 | 70% | 17335 | 14154 | 3181 | 22% |
| Change in fair value of contingent consideration |  |  |  | NM | (15000) |  | (15000) | NM |
| Project 420 business optimization |  |  |  | NM | 200 |  | 200 | NM |
| Purchase price accounting step-up |  | 1376 | (1376) | (100)% |  | 1551 | (1551) | (100)% |
| Litigation costs, net of recoveries | 869 | 901 | (32) | (4)% | 1876 | 2496 | (620) | (25)% |
| Restructuring costs | 965 | 6869 | (5904) | (86)% | 1834 | 11116 | (9282) | (84)% |
| Transaction costs (income), net | 569 | 802 | (233) | (29)% | 969 | 1958 | (989) | (51)% |
| Adjusted EBITDA | $8365 | $9017 | $(652) | (7)% | $18546 | $18351 | $195 | 1% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 41

------

Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net income (loss). There are a number of limitations related to the use of Adjusted EBITDA as compared to net income (loss), the closest comparable GAAP measure. Adjusted EBITDA adjusts for the following:

● Non-cash amortization expenses and, although these are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future;

● Stock-based compensation expenses, a non-cash expense and are an important part of our compensation strategy;

● Non-cash impairment charges, as the charges are not expected to be a recurring business activity;

● Non-cash foreign exchange gains or losses, which accounts for the effect of both realized and unrealized foreign exchange transactions. Unrealized gains or losses represent foreign exchange revaluation of foreign denominated monetary assets and liabilities;

● Non-cash change in fair value of warrant liability;

● Non-cash change in fair value of contingent consideration;

● Project 420 business optimization costs;

● Interest expense, net;

● Costs incurred to start up new facilities, and to fund emerging market operations; 

● Transaction (income) costs, net which includes acquisition related income and expenses, related legal, financial advisor and due diligence cost and expenses and transaction related compensation, which vary significantly by transaction and are excluded to evaluate ongoing operating results;

● Restructuring charges;

● Litigation costs, net of favorable recoveries and the third party fees associated with defending these claims, including costs related to legacy and non-operational litigation matters, legal settlements and recoveries;

● Amortization of purchase accounting fair value step-up in inventory value included in costs of goods sold; and

● Current and deferred income tax expenses and recoveries, which could be a significant recurring expense or recovery in our business in the future and reduce or increase cash available to us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42

------

**Adjusted Gross Profit and Adjusted Gross Margin**

Adjusted gross profit and adjusted gross margin are non-GAAP financial measures and may not be comparable to similar measures presented by other companies. Adjusted gross profit is our Gross profit (adjusted to exclude PPA valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude PPA valuation step-up) and are non-GAAP financial measures. The Company's management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin percentage in isolation or as an alternative to financial measures determined in accordance with GAAP.

**Liquidity and Capital Resources** 

We actively manage our cash, marketable securities and digital assets in order to internally fund operating needs, make scheduled interest and principal payments on our borrowings, and complete acquisitions. We believe that existing cash, cash equivalents, marketable securities, Bitcoin digital assets and cash generated by operations, together with access to external sources of funds, will be sufficient to meet our domestic and foreign capital needs for the short and long term outlook.

For the Company's short-term liquidity requirements, we are focused on generating positive cash flow from operations and being free cash flow positive. Certain of our business segments, such as cannabis, are working capital intensive and have longer cash conversion cycles. In order to mitigate these effects, management continues to optimize our infrastructure, headcount, as well as the elimination of other discretionary operational costs. Additionally, the Company continues to work on improvements to the cash conversion cycles across its businesses and invest our excess cash in short-term marketable securities, which are comprised of U.S. treasury bills, high grade corporate bonds and term deposits with major Canadian, European and Australian banks as well as in digital assets.

For the Company's long-term liquidity requirements, we are focused on funding operations through profitable organic growth and through acquisitions of businesses that are accretive to earnings and are less working capital intensive. We may need to take on additional debt or equity financing arrangements in order to achieve these target goals on a long-term basis.

On May 17, 2024, the Company entered into an equity distribution agreement with TD Securities (USA) LLC and Jefferies LLC in connection with an aggregate offering value of up to $250 million through an at-the-market equity program ("ATM Program"). During the three and six months ended November 30, 2025, the Company issued 6,777,224 shares under the ATM Program generating gross proceeds of $76.6 million. The Company paid $3.5 million in commissions and other fees associated with these issuances generating net proceeds of $73.1 million. The Company intends to use the net proceeds from the ATM Program to fund strategic and accretive acquisitions or investments in businesses and capital expenditures for acquired businesses, including potential acquisitions of assets to capitalize on expected regulatory advancements or expansion opportunities. As of November 30, 2025, the ATM program was completed.

Additionally, we are committed to optimizing our capital structure and enhancing financial flexibility as we intend to continue to opportunistically purchase or exchange equity for the TLRY 27 Notes prior to their underlying maturity date in June 2027, subject to market conditions.

The following table sets forth the major components of our statements of cash flows for the periods presented:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the three months ended** | **For the three months ended** | **For the six months ended** | **For the six months ended** |
|  | **November 30,** | **November 30,** | **November 30,** | **November 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Net cash provided by (used in) operating activities | $(8537) | $(40724) | $(9878) | $(76031) |
| Net cash provided by (used in) investing activities | (58005) | (10725) | (33538) | (60120) |
| Net cash provided by financing activities | 48100 | 38203 | 67948 | 98793 |
| Effect on cash of foreign currency translation | 317 | (2242) | 505 | (1284) |
| Cash and cash equivalents, beginning of period | 264828 | $205186 | 221666 | 228340 |
| Cash and cash equivalents, end of period | $246703 | $189698 | $246703 | $189698 |
| Marketable securities | 44848 | 62551 | 44848 | 62551 |
| Cash and marketable securities<sup>(1)</sup> | $291551 | $252249 | $291551 | $252249 |

---

*(1)* *Cash and marketable securities are non-GAAP financial measures. See* "*Use of Non-GAAP Measures*" *above for additional discussion regarding these non-GAAP measures. The Company combines the Cash and cash equivalent financial statement line item, and the Marketable securities financial statement line item as an aggregate total as reconciled in the liquidity and capital resource section below. The Company's management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combing these three GAAP metrics.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 43

------

*Cash flows from operating activities*

The change in net cash used in operating activities was ($8.5) million and ($9.9) million for three and six months ended November 30, 2025, compared to ($40.7) million and $($76.0) million for the prior year periods. The prior year periods were impacted by the integration of Craft Acquisition I, which required working capital investments and have now normalized.

*Cash flows from investing activities*

The change in net cash provided by (used in) investing activities was ($58.0) million and ($33.5) million for three and six months ended November 30, 2025, compared to ($10.7) million and ($60.1) million for the prior year periods, and was a result of the change in investments in marketable securities in the current periods and that Craft Acquisition II occurred in the prior year period.

*Cash flows from financing activities*

The change in cash provided by financing activities was $48.1 million and $67.9 million for three and six months ended November 30, 2025, compared to $38.2 million and $98.8 million for the prior year periods primarily due to variability in funds provided under the ATM Program.

**Contingencies**

In addition to the litigation described in the Part II, Item 1 - Legal Proceedings, the Company is and may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company's consolidated results of operations, financial position, cash flows or liquidity.

**Critical Accounting Estimates**

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The accounting principles we use require us to make estimates and assumptions that may impact the reported amounts of assets and liabilities as of the date of the financial statements and amounts of income and expenses during the reporting periods presented. We believe in the quality and reasonableness of our critical accounting policies, however, materially different amounts may be reported under different conditions or using assumptions different from those that we have applied. The accounting estimates that have been identified as critical to our business operations and to understanding the results of our operations pertain to revenue recognition, valuation of inventory, valuation of long-lived assets, goodwill and intangible assets, stock-based compensation and valuation allowances for deferred tax assets. The application of each of these critical accounting policies and estimates is discussed in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations set forth in, our Annual Report on Form 10-K for the fiscal year ended May 31, 2025.

**Recently Issued Accounting Pronouncements**

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in "Part I, Item 1. Note 1 – Basis of presentation and summary of significant accounting policies" to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 44

------

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

During the six months ended November 30, 2025, there have been no material changes in market risk from those addressed in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2025. See the information set forth in Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk set forth in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2025.

**Item 4. Controls and Procedures.**

*Disclosure Controls and Procedures* 

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of November 30, 2025, our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

*Changes in Internal Control over Financial Reporting*

There have been no changes in our "internal control over financial reporting" (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 45

------

**PART II**—**OTHER INFORMATION**

**Item 1. Legal Proceedings.** 

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available, our management believes that it has established appropriate legal reserves. Any liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

"Item 3. Legal Proceedings" of our Annual Report on Form 10-K for the fiscal year ended May 31, 2025 includes a discussion of our legal proceedings. There have been no material changes from the legal proceedings described in our Form 10-K, as disclosed and incorporated herein by reference to Note 19 (Commitments and contingencies) to the Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 46

------

**Item 1A. Risk Factors.**

"Item 1A. Risk Factors" of our Annual Report on Form 10-K for the fiscal year ended May 31, 2025 includes a discussion of our known material risk factors, other than risks that could apply to any issuer or offering. A summary of our risk factors is included below. Except for the below risk factors, there have been no material changes from the risk factors described in our Form 10-K.

● We may not achieve the expected revenue or other benefits from the craft beer operations we acquired in fiscal years 2024 and 2025.

● We may experience difficulties integrating operations and realizing the expected benefits of recent acquisitions, including the Craft brands acquisitions.

● Our cannabis business is dependent upon regulatory approvals and licenses, ongoing compliance and reporting obligations, and timely renewals.

● Government regulation is evolving, including potential regulatory developments in the United States to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act. In November 2025, new U.S. federal legislation was enacted that banned the production or sale of hemp-derived cannabis, including Delta-9. This restriction is scheduled to go into effect on November 12, 2026.

● We are subject to potential modifications to existing regulatory frameworks outside of North America, as well as uncertainties and potential delays in receiving required export/import permits in Europe and Australia. Any unfavorable changes to or lack of commercial legalization, or extended delays in receipt of required permits, could negatively impact our businesses and the potential planned expansion of our business.

● We face intense competition, including from the illicit cannabis market, and anticipate competition will increase, which could hurt our business.

● Our production and processing facilities are integral to our business and adverse changes or developments affecting our facilities may have an adverse impact on our business.

● Regulations constrain our ability to market and distribute our products in Canada.

● United States regulations relating to hemp-derived CBD products, Delta-9 products, and medical cannabis products are new and rapidly evolving, and changes may not develop in the timeframe or manner most favorable to our business objectives.

● Changes in consumer preferences or public attitudes about alcohol could decrease demand for our beverage products.

● SweetWater, Breckenridge, Montauk and our recently-acquired craft beer brands each face substantial competition in the beer industry or the broader market for beverage products, which could impact our business and financial results.

● We are subject to litigation, arbitration and demands, which could result in significant liability and costs, and impact our resources and reputation.

● Our business may be materially adversely affected by the imposition of duties and tariffs and other trade barriers and retaliatory countermeasures implemented by the U.S. and other governments.

● Additional impairments of our goodwill and impairments of our long-lived assets could have a material adverse impact on our financial results.

● We have a limited operating history and a history of net losses, and we may not achieve or maintain profitability in the future

● Our strategic alliances and other third-party business relationships may not achieve the intended beneficial impact and expose us to risks.

● We may not be able to successfully identify and execute future acquisitions, dispositions or other equity transactions or to successfully manage the impacts of such transactions on our operations.

● We are subject to risks inherent in an agricultural business, including the risk of crop failure.

● We depend on recurring customers for a substantial portion of our revenue. If we fail to retain or expand our customer relationships or these customers reduce their purchases, our revenue could decline significantly.

● Our products may be subject to recalls for a variety of reasons, which could require us to expend significant management and capital resources.

● Significant interruptions in our access to certain supply chains for key inputs such as raw materials, supplies, electricity, water and other utilities may impair our operations.

● Management may not be able to successfully establish and maintain effective internal controls over financial reporting.

● The price of our common stock in public markets has experienced and may continue to experience severe volatility and fluctuations.

● The volatility of our stock and the stockholder base may hinder or prevent us from engaging in beneficial corporate initiatives.

● We may not have the ability to raise the funds necessary to settle conversions of the convertible securities in cash or to repurchase the convertible securities upon a fundamental change.

● Our cryptocurrency strategy faces high risk and uncertainty in light of market volatility and an evolving regulatory landscape.

● We are subject to other risks generally applicable to our industry and the conduct of our business.

***There are regulatory risks associated with the rescheduling of cannabis in the U.S. and uncertainties in the implementation of our planned medical cannabis platform.***

The recently announced U.S. federal cannabis rescheduling order has introduced significant uncertainty regarding the scope, timing, and ultimate impact of potential changes to U.S. federal cannabis regulation. Our business, financial condition, and results of operations may be materially adversely affected if such changes do not occur as or when anticipated or impose requirements we are unable to meet. Although federal cannabis rescheduling is expected to create expanded opportunities for our business in the U.S., including our planned launch of a medical cannabis platform in 2026, the final outcome of federal rulemaking—along with related DEA and FDA oversight, enforcement priorities, and interaction with state-level regulatory frameworks—remains unclear and may materially differ from current expectations. Legal challenges to rescheduling, shifts in federal or state regulatory priorities, or the imposition of restrictive compliance, manufacturing, or distribution requirements could delay, limit, or prevent our ability to commercialize medical cannabis products in the U.S. If the resulting regulatory environment is more restrictive than anticipated, is not implemented on a timely basis, or otherwise fails to permit a viable market pathway, we may be unable to pursue our planned U.S. medical cannabis strategy as intended, which could adversely impact our growth prospects, strategic objectives, and anticipated investments.

***We may be exposed to financial losses and operational risks due to our decision to self-insure certain real property assets.***

We recently transitioned several of our real property assets from third-party insurance coverage to a self-insurance model. Under this approach, we bear the financial risk associated with potential losses, damages, business interruption, remediation costs, or other liabilities relating to these properties. While we believe this strategy appropriately balances cost management and risk, it exposes us to risks that could materially and adversely affect our business, financial condition, and results of operations. Loss events such as fire, flooding, natural disasters, equipment failures, structural degradation, theft, or other property-related incidents, could require significant out-of-pocket expenditures. Depending on the nature and magnitude of any such event, we may incur substantial unplanned costs, experience facility downtime, or have reduced capacity to cultivate, manufacture, store, or distribute products. These outcomes could disrupt supply chains, delay production, impair revenue generation, or necessitate capital expenditures not otherwise planned. In addition, our determination of appropriate reserves and internal risk-mitigation processes may prove inadequate. If the scope, frequency, or severity of property-related losses exceeds our expectations, we may experience materially higher expenses or capital requirements. Any of these factors, individually or in the aggregate, could materially and adversely impact our operating results, cash flows, and liquidity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 47

------

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

**Recent Sales of Unregistered Equity Securities**

On October 9, 2025, Tilray entered into an assignment and assumption agreement with Double Diamond Holdings Ltd. ("DDH"), an Ontario corporation, pursuant to which, among other things, Tilray acquired from DDH a promissory note in the amount of $14,821 (the "Note") payable by 1974568 Ontario Limited ("Aphria Diamond"). DDH is a joint venturer with Aphria Inc. (Tilray's wholly-owned subsidiary) in Aphria Diamond. As consideration for the Note, Tilray issued 861,707 shares of its Common Stock to DDH.

The shares of Common Stock issued in the foregoing transaction were issued without registration under the Securities Act of 1933, as amended, in reliance on the exemption provided by Section 3(a)(9) thereunder as securities exchanged by the Company with an existing security holder where no commission or other remuneration was paid or given directly or indirectly for soliciting such exchange.

**Item 3. Defaults Upon Senior Securities.**

Not applicable.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item *5.* Other Information.**

*Not* applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 48

------

**Item 6. Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 3.1 | [Certificate of Amendment of the Fifth Amended and Restated Certificate of Incorporation of the Company, filed on November 26, 2025 (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 26, 2025).](http://www.sec.gov/Archives/edgar/data/1731348/000143774925036448/ex_892363.htm) |
| 31.1\* | [Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_873929.htm) |
| 31.2\* | [Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](ex_873934.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_873935.htm) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 49

------

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| 32.2\*\* | [Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](ex_873936.htm) |
| 101\* | The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended November 30, 2025, formatted in Inline XBRL: (i) Consolidated Statements of Financial Position, (ii) Consolidated Statements of Loss and Comprehensive Loss , (iii) Consolidated Statements of Stockholders' Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Condensed Interim Consolidated Financial Statements, tagged as blocks of text and including detailed tags. |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed herewith.

\*\* Furnished herewith.

†&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Tilray Brands, Inc. | Tilray Brands, Inc. |
| Date: January 8, 2026 | By: | /s/ Irwin D. Simon |
|  |  | **Irwin D. Simon** |
|  |  | **Chairman and Chief Executive Officer** |
| Date: January 8, 2026 | By: | /s/ Carl Merton |
|  |  | **Carl Merton** |
|  |  | **Chief Financial Officer** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 51

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Irwin D. Simon, certify that:

1. I have reviewed this Form 10-Q of Tilray Brands, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 8, 2026 | By: | /s/ Irwin D. Simon |
|  |  | **Irwin D. Simon** |
|  |  | **Chairman and Chief Executive Officer** |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Carl A. Merton, certify that:

1. I have reviewed this Form 10-Q of Tilray Brands, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: January 8, 2026 | By: | /s/ Carl A. Merton |
|  |  | **Carl A. Merton** |
|  |  | **Chief Financial Officer** |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Tilray Brands, Inc. (the "Company") on Form 10-Q for the period ending November 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: January 8, 2026 | By: | /s/ Irwin D. Simon |
|  |  | **Irwin D. Simon** |
|  |  | **Chairman and Chief Executive Officer** |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report of Tilray Brands, Inc. (the "Company") on Form 10-Q for the period ending November 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: January 8, 2026 | By: | /s/ Carl A. Merton |
|  |  | **Carl A. Merton** |
|  |  | **Chief Financial Officer** |

---